[
    {
        "content": "NEW YORK A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.",
        "date": "11162017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson hit with $247 million verdict in hip implant trial "
    },
    {
        "content": "A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.",
        "date": "11162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer "
    },
    {
        "content": "Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.",
        "date": "11162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J wins California lawsuit claiming asbestos in talc caused cancer "
    },
    {
        "content": "NEW YORK  Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.",
        "date": "11162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Johnson & Johnson hit with $247 mln verdict in hip implant trial "
    },
    {
        "content": "Nov 16 A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.",
        "date": "11162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J wins Calif. lawsuit claiming asbestos in talc caused cancer "
    },
    {
        "content": "NEW YORK  Nov 16 A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.",
        "date": "11162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson hit with $247 mln verdict in hip implant trial "
    },
    {
        "content": "SEOUL  Nov 14 A unit of healthcare conglomerate Johnson & Johnson has dropped a lawsuit it filed to block a copy of its rheumatoid arthritis drug Remicade produced by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.",
        "date": "11142017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy "
    },
    {
        "content": "* Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics",
        "date": "11132017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation "
    },
    {
        "content": "Johnson & Johnson subsidiary Ethicon was not liable for the injuries that a Texas woman blamed on the company's pelvic mesh device  a federal jury decided on Thursday.",
        "date": "11102017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Ethicon cleared of liability in another federal pelvic mesh trial "
    },
    {
        "content": "Private equity firm Carlyle Group LP is exploring a sale or initial public offering of Ortho-Clinical Diagnostics Inc  a U.S. diagnostics company that could be valued at more than $7 billion  including debt  people familiar with the matter said.",
        "date": "11102017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Exclusive: Carlyle explores sale or IPO of Ortho-Clinical Diagnostics - sources "
    },
    {
        "content": "More than 1 200 women suing Johnson & Johnson claiming its talc-based products cause ovarian cancer have been given the green light to examine communications between J&J and other companies regarding foreign regulation of talc products.",
        "date": "11072017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Women in J&J talc MDL allowed access to third-party documents "
    },
    {
        "content": "Nov 4 Johnson & Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial  according to data released on Saturday.",
        "date": "11042017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's Stelara shows promise against lupus in study "
    },
    {
        "content": "* Stelara\u00ae (ustekinumab) shows positive results in treatment of systemic lupus erythematosus in phase 2 trial",
        "date": "11062017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J's Stelara shows positive results in treatment of systemic lupus erythematosus in phase 2 trial "
    },
    {
        "content": "Nov 4 Johnson & Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial  according to data released on Saturday.",
        "date": "11062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "RPT-J&J's Stelara shows promise against lupus in study "
    },
    {
        "content": "Lawyers for the family of an Alabama woman who blamed her death from ovarian cancer on her use of Johnson & Johnson talc-based products have asked a Missouri appeals court to revisit its decision to overturn a $72 million verdict against the company.",
        "date": "11012017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Alabama woman's family seeks reconsideration of J&J talc ruling "
    },
    {
        "content": "FRANKFURT  Nov 6 German drugmaker Bayer on Monday moved to tap a potentially lucrative new market opportunity for its blockbuster clot prevention drug Xarelto  requesting approval in Europe to make atherosclerosis patients eligible for treatment.",
        "date": "11062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bayer in bid to broaden use of anti-clotting drug Xarelto "
    },
    {
        "content": "* Janssen Inc. announces Imbruvica\u00ae (ibrutinib) as the first approved treatment for chronic graft-versus-host disease (CGVHD) granted by Health Canada priority review",
        "date": "10302017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J's Janssen announces Imbruvica as the first approved treatment for chronic graft-versus-host disease granted by Health Canada priority review "
    },
    {
        "content": "Johnson & Johnson's orthopedics unit DePuy has called on a federal judge to toss an ongoing trial over the company's metal-on-metal hip implants  saying plaintiffs had prejudiced the jury by making inappropriate references to other hip litigation.",
        "date": "10262017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J calls opposing counsel inflammatory  asks for mistrial in Pinnacle hip case "
    },
    {
        "content": "LONDON Pfizer plans to kick off an auction process for its consumer healthcare business in November  paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business  sources close to the matter told Reuters.",
        "date": "10262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Exclusive: Pfizer to launch consumer health sale in November - sources "
    },
    {
        "content": "A California judge on Friday threw out a $417 million verdict against Johnson & Johnson  in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.",
        "date": "10212017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "California judge tosses $417 million talc cancer verdict against Johnson & Johnson "
    },
    {
        "content": "Oct 20 A California judge on Friday threw out a $417 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.",
        "date": "10212017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "California judge tosses $417 mln talc cancer verdict against J&J "
    },
    {
        "content": "* Arcturus Therapeutics announces strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines",
        "date": "10192017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Arcturus Therapeutics to collaborate with Johnson & Johnson "
    },
    {
        "content": "The Missouri Supreme Court has ordered a St. Louis judge to hold off on conducting the latest trial over claims Johnson & Johnson's talc-based products can cause ovarian cancer  which had been scheduled to begin Monday.",
        "date": "10162017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Top Missouri court blocks latest J&J talc trial "
    },
    {
        "content": "* Sets quarterly cash dividend of $0.84 per share Source text for Eikon: Further company coverage:",
        "date": "10192017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J sets quarterly cash dividend of $0.84 per share "
    },
    {
        "content": "* \u200djohnson & Johnson Medical Devices Companies says definitive agreement to acquire German software company  Surgical Process Institute\u200b",
        "date": "10192017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-\u200dJohnson & Johnson Medical GmbH to acquire Surgical Process Institute\u200b "
    },
    {
        "content": "Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks "
    },
    {
        "content": "Oct 17 Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J wins reversal of $72 mln verdict over talc cancer risks "
    },
    {
        "content": "Johnson & Johnson posted better-than-expected third-quarter earnings  raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "New cancer drugs help Johnson & Johnson top profit estimates "
    },
    {
        "content": "* Shares rise 2.4 pct (Adds detail about talc verdict in last paragraph)",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 5-New cancer drugs help J&J top profit estimates "
    },
    {
        "content": "Oct 17 Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company's talc-based products like Johnson's Baby Powder.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J wins reversal of $72 million verdict over talc cancer risks "
    },
    {
        "content": "Oct 17 The Dow Industrials breached the 23 000 mark for the first time on Tuesday  helped by a rally in shares of UnitedHealth and Johnson & Johnson.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS SNAPSHOT-Dow cracks 23 000 mark for the first time "
    },
    {
        "content": "NEW YORK  Oct 17 Johnson & Johnson said all of its manufacturing sites on Puerto Rico are running again after Hurricane Maria hit the island last month  but it cannot rule out intermittent shortages of some of its drugs.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's Puerto Rico plants running  can't rule out shortages "
    },
    {
        "content": "Oct 13 Johnson & Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition.",
        "date": "10132017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J psoriasis drug gets expanded U.S. approval for teens "
    },
    {
        "content": "A California judge on Tuesday declared a mistrial in a closely watched trial over claims Johnson & Johnson's talc-based products such as Johnson's Baby Powder contained asbestos and caused a woman to develop mesothelioma.",
        "date": "10102017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Mistrial in case claiming J&J talc products contained asbestos "
    },
    {
        "content": "* Indexes up: Dow 0.09 pct  S&P 0.08 pct  Nasdaq 0.11 pct (Updates to early afternoon)",
        "date": "10112017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "US STOCKS-Dow inches up to record-high on gains in J&J  Wal-Mart "
    },
    {
        "content": "* Q3 earnings per share view $1.80 -- Thomson Reuters I/B/E/S",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson Q3 earnings per share $1.37 "
    },
    {
        "content": "Oct 17 Johnson & Johnson  which completed its $30 billion acquisition of Swiss biotech Actelion in June  reported a 11.9 percent fall in quarterly profit as costs rose.",
        "date": "10172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J reports 11.9 pct fall in quarterly profit "
    },
    {
        "content": "FRANKFURT/BERLIN Bayer stood by its peak sales estimate for clot prevention drug Xarelto after the pill disappointed in a late-stage trial to test prevention of repeat strokes.",
        "date": "10062017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Bayer sticks by Xarelto sales estimate despite study setback "
    },
    {
        "content": "* Trial was on secondary prevention of stroke  embolism (Adds peak sales estimate)",
        "date": "10062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Bayer sticks by Xarelto sales estimate despite study setback "
    },
    {
        "content": "VALENCIA  Venezuela Venezuelan auto worker Celso Nunez spends his days moonlighting as a mover and trading salvaged building materials in his worn-out red pick-up.",
        "date": "10062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Awaiting better days  multinationals keep Venezuela units alive - barely "
    },
    {
        "content": "BERLIN  Oct 6 Bayer and partner Johnson & Johnson suffered a setback for blockbuster clot prevention drug Xarelto  with the German company saying a Phase III study had been halted early after the drug showed no efficacy improvements over low-dose aspirin.",
        "date": "10062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bayer says Phase III Xarelto study halted early "
    },
    {
        "content": "* Johnson & Johnson announces completion of Codman Neurosurgery divestiture to Integra Lifesciences Holding Corporation Source text for Eikon: Further company coverage:",
        "date": "10022017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-JNJ announces completion of Codman Neurosurgery divestiture to Integra Lifesciences "
    },
    {
        "content": "Johnson & Johnson's diabetes care unit  which makes insulin pumps  said on Thursday it would shut its business in United States and Canada amid increased competition and after failing to find a buyer.",
        "date": "10052017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson unit exits insulin pump business amid rising competition "
    },
    {
        "content": "Oct 5 Johnson & Johnson's diabetes care unit  which makes insulin pumps  said on Thursday it would shut its business in United States and Canada amid increased competition and after failing to find a buyer.",
        "date": "10052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J unit exits insulin pump business amid rising competition "
    },
    {
        "content": "Oct 5 Animas Corp  Johnson & Johnson's diabetes care unit  said it intends to exit the insulin pump business and has selected Medtronic Plc as its partner for patients on insulin pumps.",
        "date": "10052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's diabetes care unit to exit insulin pump business "
    },
    {
        "content": "* \u200dJohnson & Johnson Diabetes Care Companies - Animas corp intends to discontinue manufacturing  sale of animas vibe and onetouch ping insulin pumps",
        "date": "10052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J diabetes care company Animas to close operations and exit insulin pump market "
    },
    {
        "content": " The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab  saying additional clinical data is needed to further evaluate its safety  the company said on Friday.",
        "date": "09252017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA declines to approve J&J arthritis drug sirukumab "
    },
    {
        "content": "Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab  saying additional clinical data is needed to further evaluate its safety  the company said on Friday.",
        "date": "09252017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab "
    },
    {
        "content": "BOSTON A U.S. appeals court on Wednesday refused to reconsider a ruling reviving a lawsuit claiming Johnson & Johnson's DePuy Orthopaedics Inc unit marketed defective hip replacement devices to doctors who then sought government reimbursement.",
        "date": "09272017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "1st Circuit won't reconsider J&J's DePuy whistleblower case ruling "
    },
    {
        "content": "Sept 27 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "09272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "WASHINGTON Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division  the Federal Trade Commission said on Wednesday.",
        "date": "09272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FTC approves Integra purchase of J&J\u2019s Codman business "
    },
    {
        "content": "WASHINGTON Medical device maker Integra LifeSciences Holdings Corp  has received U.S. antitrust approval to buy Johnson & Johnson's  Codman Neuro Division  the Federal Trade Commission said on Wednesday.",
        "date": "09272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. FTC approves Integra purchase of J&J\u2019s Codman business "
    },
    {
        "content": "WASHINGTON  Sept 27 Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division  the Federal Trade Commission said on Wednesday.",
        "date": "09272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-U.S. FTC approves Integra purchase of J&J\u2019s Codman business "
    },
    {
        "content": "WASHINGTON  Sept 27 Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division  the Federal Trade Commission said on Wednesday.",
        "date": "09272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FTC allows Integra to buy J&J\u2019s Codman neuro business  with conditions "
    },
    {
        "content": "Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab  saying additional clinical data is needed to further evaluate its safety  the company said on Friday.",
        "date": "09222017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "U.S. FDA rejects J&J's arthritis drug "
    },
    {
        "content": "A Johnson & Johnson subsidiary has lost a bid to dismiss claims that it retaliated against a former employee whose whistleblower lawsuit led to an $18 million settlement with the U.S. Justice Department.",
        "date": "09212017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J unit loses bid to dismiss whistleblower's retaliation claims "
    },
    {
        "content": "Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson  saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug  Remicade  were anticompetitive and blocked sales of Pfizer's new biosimilar.",
        "date": "09202017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Pfizer files suit against J&J over Remicade contracts "
    },
    {
        "content": "Sept 20 Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson  saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug  Remicade  were anticompetitive and blocked sales of Pfizer's new biosimilar.",
        "date": "09202017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-Pfizer files suit against J&J over Remicade contracts "
    },
    {
        "content": "Sept 20 Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson  saying that the drugmaker's anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug  Remicade.",
        "date": "09202017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Pfizer sues Johnson & Johnson over Remicade biosimilar "
    },
    {
        "content": "The drug industry's largest trade group is urging a federal appeals court to reconsider a decision reviving a whistleblower lawsuit against Johnson & Johnson  saying it incorrectly relaxed standards that can protect companies from \"parasitic\" lawsuits.",
        "date": "09182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "PhRMA urges 1st Circuit to reconsider J&J whistleblower ruling "
    },
    {
        "content": "A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug  guselkumab  for the treatment of plaque psoriasis in adults.",
        "date": "09152017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "European panel backs Janssen's psoriasis drug "
    },
    {
        "content": "* \u200dPfizer says filed suit in U.S. District Court for Eastern District of Pennsylvania against Johnson & Johnson\u200b",
        "date": "09202017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-\u200dPfizer files lawsuit against Johnson & Johnson\u200b "
    },
    {
        "content": "Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug  guselkumab  for the treatment of plaque psoriasis in adults.",
        "date": "09152017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-European panel backs Janssen's psoriasis drug "
    },
    {
        "content": "Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug  guselkumab  for the treatment of plaque psoriasis in adults.",
        "date": "09152017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "European panel recommends approval of J&J's psoriasis drug "
    },
    {
        "content": "Janssen Sciences Ireland UC  a unit of Johnson & Johnson  said it would discontinue further development of its hepatitis C research  citing increased availability of a number of effective hepatitis C therapies.",
        "date": "09112017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J unit ends hepatitis C drug development in crowded market "
    },
    {
        "content": "A Pennsylvania jury on Thursday found Johnson & Johnson subsidiary Ethicon liable for the injuries of a woman who had been implanted with two of the company's pelvic mesh devices  awarding her $57 million  the highest in a pelvic mesh case to date.",
        "date": "09072017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J hit with $57 mln verdict in latest pelvic mesh trial "
    },
    {
        "content": "COPENHAGEN Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019  if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year  a company executive said.",
        "date": "08252017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Bavarian Nordic says first milestone payment under J&J deal could be in 2019 "
    },
    {
        "content": "* But may take on some risk in respiratory diseases (adds detail on RSV  Prostvac and partnerships)",
        "date": "08252017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Bavarian Nordic says first milestone payment under J&J deal could be in 2019 "
    },
    {
        "content": "COPENHAGEN  Aug 25 Danish biotech company Bavarian Nordic expects to get a first milestone payment under a new deal with Janssen Pharmaceuticals in 2019  if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year  a company executive said.",
        "date": "08252017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bavarian Nordic says first milestone payment under new J&J deal could be in 2019 "
    },
    {
        "content": "NEW YORK A massive California verdict in a lawsuit alleging Johnson & Johnson's  talc-based products cause cancer has opened a new front in the litigation  upending the company's hopes that the cases were only gaining traction in Missouri  legal experts said.",
        "date": "08232017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Massive California verdict expands J&J's talc battlefield "
    },
    {
        "content": "A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.",
        "date": "08212017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J ordered to pay $417 million in trial over talc cancer risks "
    },
    {
        "content": "Aug 21 Johnson & Johnson on Monday was ordered by a California jury to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.",
        "date": "08212017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J ordered to pay $417 mln in trial over talc cancer risks "
    },
    {
        "content": "Aug 21 A California jury on Monday ordered Johnson & Johnson to pay $417 million to a woman who claimed she developed ovarian cancer after using the company's talc-based products like Johnson's Baby Powder for feminine hygiene.",
        "date": "08212017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J ordered to pay $417 mln in trial over talc cancer risks "
    },
    {
        "content": "Aug 18 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.",
        "date": "08182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bayer  J&J win third U.S. trial over Xarelto bleeding risk "
    },
    {
        "content": "Johnson & Johnson has convinced a federal judge that a recent U.S. Supreme Court ruling requires the dismissal of claims in Missouri state court by 53 out-of-state plaintiffs over injuries they blame on the antipsychotic drugs Risperdal and Invega.",
        "date": "08112017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Judge tosses 53 plaintiffs' claims against J&J over Risperdal "
    },
    {
        "content": "* Bavarian Nordic A/S says subscription price is dkk 405.1578 per share of dkk 10",
        "date": "08092017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Bavarian Nordic announces price for shares to be issued to Johnson & Johnson Innovation "
    },
    {
        "content": "Johnson & Johnson has suffered another setback in its efforts to use a recent U.S. Supreme Court ruling to dismiss claims by hundreds of women and their family members in Missouri state court that its talc products can cause ovarian cancer.",
        "date": "08042017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J loses another round in fight to toss Missouri talc cases "
    },
    {
        "content": "The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks  an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.",
        "date": "08032017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA panel votes against approval of J&J arthritis drug "
    },
    {
        "content": "The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks  an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.",
        "date": "08022017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA panel votes against approval of J&J arthritis drug "
    },
    {
        "content": "Aug 2 The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks  an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.",
        "date": "08022017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-U.S. FDA panel votes against approval of J&J arthritis drug "
    },
    {
        "content": "Aug 2 The benefits of Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab do not outweigh the risks and it should not be approved  an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday.",
        "date": "08022017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. FDA panel votes against approval of J&J arthritis drug "
    },
    {
        "content": "There were more deaths in patients taking Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo  staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.",
        "date": "07312017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J arthritis drug sirukumab raises safety concerns: FDA staff "
    },
    {
        "content": "July 31 There were more deaths in patients taking Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab than among those taking a placebo  staff reviewers for the U.S. Food and Drug Administration said in a report published Monday.",
        "date": "07312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J arthritis drug sirukumab raises safety concerns -FDA staff "
    },
    {
        "content": "July 31 Staff reviewers for the U.S. Food and Drug Administration noted on Monday that there was a trend of increased death with Johnson & Johnson's experimental rheumatoid arthritis drug sirukumab compared with placebo.",
        "date": "07312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J arthritis drug sirukumab raises safety concerns - FDA staff "
    },
    {
        "content": "* Proteros enters into new research collaboration with Johnson & Johnson innovation on sub-class of epigenetic targets Source text for Eikon:",
        "date": "07272017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Proteros enters into new research collaboration with Johnson & Johnson innovation on sub-class of epigenetic targets "
    },
    {
        "content": "* Global M&A environment remains favorable - CEO (Adds Breakingviews link)",
        "date": "07272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-Lazard profit beats on record advisory  asset management revenue "
    },
    {
        "content": "July 27 Danish biotech company Bavarian Nordic has expanded its collaboration with Janssen Pharmaceuticals  a unit of Johnson & Johnson  to also grant the U.S. drugmaker the exclusive rights to its MVA-BN technology for vaccine programmes targeting hepatitis B and HIV-1.",
        "date": "07272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Bavarian expands J&J deal to HIV and hepatitis B vaccines  shares jump "
    },
    {
        "content": "A lawyer for Johnson & Johnson on Wednesday urged jurors to not find it liable in the first trial the company has faced in California over claims that its talc-based products for feminine hygiene can cause ovarian cancer.",
        "date": "07272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J faces first California trial over talc cancer risks "
    },
    {
        "content": "NEW YORK  July 24 The Nasdaq hit a record high on Monday ahead of a big week of technology earnings reports  while the S&P 500 and the Dow industrials lagged behind as losses in healthcare heavyweight Johnson & Johnson took a toll.",
        "date": "07242017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "US STOCKS SNAPSHOT-J&J weighs on Dow  S&P; Nasdaq hits record "
    },
    {
        "content": "NEW YORK/SEOUL  July 24 Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States  a move that should accelerate price declines for the big-selling medicine.",
        "date": "07242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Merck  Samsung Bioepis launch discounted U.S. Remicade alternative "
    },
    {
        "content": "* Indexes down: Dow 0.32 pct  S&P 0.21 pct  Nasdaq 0.03 pct (Adds details  changes comment  updates prices)",
        "date": "07242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-S&P  Dow lower as Johnson & Johnson drags "
    },
    {
        "content": "* EU Medicines Agency recommends approval of Johnson & Johnson unit Janssen-Cilag International N.V. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Symtuza) drug for HIV Source text ID:  (http://bit.ly/2vIbPPG) Further company coverage:",
        "date": "07212017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-EU Medicines Agency recommends approval J&J unit's Symtuza drug for HIV "
    },
    {
        "content": "* Gov't  drugmakers agreed price cuts of as much as 70 pct (Adds picture)",
        "date": "07192017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "UPDATE 2-China adds blockbuster drugs to insurance list after price cuts "
    },
    {
        "content": "Johnson & Johnson  said it expects sales growth to pick up in the second half of the year on strong demand for newer  pricey treatments such as cancer drugs Darzalex and Imbruvica.",
        "date": "07182017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J sees sales growth in near-term; raises 2017 profit forecast "
    },
    {
        "content": "* Sets quarterly cash dividend of $0.84 per share Source text for Eikon: Further company coverage:",
        "date": "07172017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J sets quarterly cash dividend of $0.84 per share "
    },
    {
        "content": "* Pharmaceutical sales miss estimates for third straight qtr -RBC",
        "date": "07182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 5-J&J sees sales growth in near-term; raises 2017 profit forecast "
    },
    {
        "content": "* Pharmaceutical sales miss estimates for third straight qtr - RBC",
        "date": "07182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-UPDATE 4-J&J sees sales growth in near-term; raises 2017 profit forecast "
    },
    {
        "content": "July 18 Johnson & Johnson  which completed its $30 billion acquisition of Swiss biotech Actelion last month  reported a 4.3 percent fall in quarterly profit  as costs rose.",
        "date": "07182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J reports dip in quarterly profit "
    },
    {
        "content": "PARIS  July 11 French drugmaker and healthcare group Sanofi is to buy privately-held U.S vaccines biotech company Protein Sciences for an initial amount of $650 million  as Sanofi steps up its acquisition programme after recently missing two large deals.",
        "date": "07112017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Sanofi to buy vaccines biotech group Protein Sciences "
    },
    {
        "content": "SYDNEY  July 4 Australian women have brought a class-action case against Johnson & Johnson over complications arising from vaginal mesh implants - a lawsuit that follows many others in the United States  Canada and Europe.",
        "date": "07042017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Australian class action suit filed against Johnson & Johnson over pelvic mesh "
    },
    {
        "content": "June 21 Missouri's attorney general on Wednesday announced a lawsuit against three major drug manufacturers claiming they fraudulently misrepresented the risks posed by opioid painkillers now at the center of a national addiction epidemic.",
        "date": "06212017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Missouri attorney general sues opioid manufacturers "
    },
    {
        "content": "Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.",
        "date": "06212017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. Supreme Court ruling threatens massive talc litigation against J&J "
    },
    {
        "content": "June 20 Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.",
        "date": "06212017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "RPT-U.S. Supreme Court ruling threatens massive talc litigation against J&J "
    },
    {
        "content": "June 20 Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.",
        "date": "06212017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-U.S. Supreme Court ruling threatens massive talc litigation against J&J "
    },
    {
        "content": "ZURICH Shares in Idorsia   the drug pipeline firm spun off from biotech group Actelion  after Johnson & Johnson's  $30 billion takeover  rose nearly 30 percent after making their market debut at 10 Swiss francs each on Friday.",
        "date": "06162017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Actelion spin-off Idorsia's shares rise 30 pct in market debut "
    },
    {
        "content": "ZURICH  June 16 Shares in Idorsia  the drug pipeline firm spun off from biotech group Actelion after Johnson & Johnson's $30 billion takeover  rose nearly 30 percent after making their market debut at 10 Swiss francs each on Friday.",
        "date": "06162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Actelion spin-off Idorsia's shares rise 30 pct in market debut "
    },
    {
        "content": "ZURICH  June 16 Shares in Idorsia  the drug pipeline company spun off from biotech group Actelion after Johnson & Johnson's $30 billion takeover  made their market debut at 10 Swiss francs per share on Friday.",
        "date": "06162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion spin-off Idorsia makes market debut at 10 Sfr per share "
    },
    {
        "content": "* Actelion announces completion of acquisition of Actelion Ltd by Johnson & Johnson for a total purchase price of approximately $30 billion in cash Further company coverage: (Reporting By Zurich newsroom)",
        "date": "06162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J completes $30 bln takeover of Actelion "
    },
    {
        "content": "* Johnson & Johnson announces completion of acquisition of Actelion",
        "date": "06162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson announces completion of acquisition of Actelion "
    },
    {
        "content": "June 14 Johnson & Johnson said on Wednesday its experimental flu drug significantly reduced viral load compared to a placebo in a mid-stage study of patients with a type of influenza.",
        "date": "06142017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson's flu drug succeeds in mid-stage trial "
    },
    {
        "content": "June 14 Diversified healthcare company Johnson & Johnson said on Wednesday its experimental flu drug significantly reduced the presence of the virus in patients with a type of influenza in a mid-stage study.",
        "date": "06142017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Johnson & Johnson's flu drug succeeds in mid-stage trial "
    },
    {
        "content": "* Johnson & Johnson medical devices companies says are working with medical University of South Carolina",
        "date": "06142017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson says are working with medical University of South Carolina "
    },
    {
        "content": "June 12 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto  the drug companies said on Monday. (Reporting by Nate Raymond in Boston; Editing by Dan Grebler)",
        "date": "06122017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bayer  J&J win second U.S. trial over Xarelto bleeding risks "
    },
    {
        "content": "June 12 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto  the drug companies said on Monday.",
        "date": "06122017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Bayer  J&J win second U.S. trial over Xarelto bleeding risks "
    },
    {
        "content": "A lawyer for Johnson & Johnson on Friday told jurors that the allegation its talc-based products for feminine hygiene can cause ovarian cancer is an \"unspeakable lie \" as the latest trial in Missouri state court over such claims got underway.",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Latest talc trial against J&J starts in St. Louis "
    },
    {
        "content": "* Named Susan Podlogar as Executive Vice President and Chief Human Resources Officer",
        "date": "06122017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Metlife names Susan Podlogar Chief Human Resources Officer "
    },
    {
        "content": "* Johnson & Johnson announces expected settlement of Actelion tender offer on June 16  2017",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson says expects settlement of Actelion tender offer on June 16  2017 "
    },
    {
        "content": "* Qualcomm announces agreement with Lifescan Inc  a Johnson & Johnson diabetes care company  to inform patient care with connected blood glucose meters",
        "date": "06122017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Qualcomm announces agreement with Lifescan Inc "
    },
    {
        "content": "BRUSSELS  June 9 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "EU mergers and takeovers (June 9) "
    },
    {
        "content": "ZURICH Swiss biotechnology company Actelion on Thursday presented mixed trial results for its antibiotic hopeful cadazolid  saying it met the main goal of one late-stage study but failed to hit the target in a second  identical study.",
        "date": "06082017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Actelion antibiotic misses mark on one study  hits it on another "
    },
    {
        "content": "* J&J Spokesperson says study enrollment in Niraparib is on temporary hold & co anticipates re-opening enrollment soon \u200d\u200b",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J Spokesperson says study enrollment in Niraparib is on temporary hold  anticipates re-opening enrollment soon \u200d\u200b "
    },
    {
        "content": "ZURICH Johnson & Johnson  said the approval of its proposed acquisition of Swiss biotech firm Actelion  by the European Commission on Friday meant all regulatory approvals required to complete the $30 billion deal had now been received.",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson expects to complete Actelion purchase on June 16 "
    },
    {
        "content": "ZURICH  June 9 Johnson & Johnson said the approval of its proposed acquisition of Swiss biotech firm Actelion by the European Commission on Friday meant all regulatory approvals required to complete the $30 billion deal had now been received.",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Johnson & Johnson expects to complete Actelion purchase on June 16 "
    },
    {
        "content": "ZURICH  June 8 The Swiss blue-chip SMI was seen opening up 0.19 percent at 8 894 points on Thursday  according to premarket indications by bank Julius Baer .",
        "date": "06082017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Swiss stocks - Factors to watch on June 8 "
    },
    {
        "content": "ZURICH  June 9 Johnson & Johnson said Friday's approval of its proposed acquisition of Swiss biotech company Actelion by the European Commission meant all regulatory approvals required to complete the $30 billion deal have been received.",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson expects to complete of Actelion offer on June 16 "
    },
    {
        "content": "June 5 Credit Suisse Group AG has hired Cory Rapkin as vice chairman in the healthcare group of its investment banking and capital markets division  according to an internal memo seen by Reuters and confirmed by a spokesman from Credit Suisse.",
        "date": "06052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "MOVES-Credit Suisse hires Rapkin for healthcare investment banking "
    },
    {
        "content": "BRUSSELS  June 9 EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion Pharmaceutical subject to conditions intended to ensure clinical development of insomnia drugs were unaffected.",
        "date": "06092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "EU approves J&J purchase of Actelion subject to conditions "
    },
    {
        "content": "Bayer AG and Johnson & Johnson are set to return to a New Orleans federal courthouse on Tuesday with a goal of scoring their second trial win amid thousands of lawsuits blaming injuries on the blood thinner Xarelto.",
        "date": "05252017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Bayer  J&J to face second trial over Xarelto bleeding risks "
    },
    {
        "content": "A state court jury in Philadelphia on Friday ordered Johnson & Johnson to pay $2.16 million to a Pennsylvania woman who claimed she suffered injuries due to pelvic mesh devices manufactured by the company's Ethicon unit.",
        "date": "05262017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Ethicon hit with $2.16 million verdict in vaginal-mesh case "
    },
    {
        "content": "Johnson and Johnson and its Janssen Pharmaceuticals unit must face claims that they concealed the risks of the antibiotic Levaquin from an Illinois woman who said she suffered debilitating side effects from the drug  a federal judge ruled.",
        "date": "05312017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Judge allows fraudulent concealment claim over J&J antibiotic "
    },
    {
        "content": "Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol  Motrin  Benadryl and other over-the-counter drugs that were eventually recalled.",
        "date": "05242017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J settles drug manufacturing probe by U.S. states for $33 mln "
    },
    {
        "content": "May 31 The state of Ohio on Wednesday sued five major drug manufacturers  accusing them of misrepresenting the risks of prescription opioid painkillers that have fueled a sky-rocketing drug addiction epidemic.",
        "date": "05312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 4-Ohio sues five drug companies over opioid crisis "
    },
    {
        "content": "May 24 Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind several over-the-counter drugs that were eventually recalled.",
        "date": "05242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J settles drug manufacturing probe by U.S. states for $33 million "
    },
    {
        "content": "The state of Ohio on Wednesday sued five major drug manufacturers  accusing them of misrepresenting the risks of prescription opioid painkillers that have fueled a sky-rocketing drug addiction epidemic.",
        "date": "05312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Ohio sues five drug companies over opioid crisis "
    },
    {
        "content": "May 24 Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol  Motrin  Benadryl and other over-the-counter drugs that were eventually recalled.",
        "date": "05242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-J&J settles drug manufacturing probe by U.S. states for $33 mln "
    },
    {
        "content": "BRUSSELS  May 18 U.S. healthcare giant Johnson & Johnson has offered concessions in a bid to address EU antitrust concerns over its $30 billion bid for Swiss biotech company Actelion  the European Commission said on Thursday.",
        "date": "05182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson offers EU concessions over Actelion deal "
    },
    {
        "content": "SEOUL  May 19 A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.",
        "date": "05192017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy "
    },
    {
        "content": "* J&J says expects more than 10 new products to launch or file for regulatory approval by 2021",
        "date": "05172017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J says expects more than 10 new products to launch or file for regulatory approval by 2021 "
    },
    {
        "content": "Johnson & Johnson  is required to add new warnings to its diabetes drug  Invokana  about the risk of foot and leg amputations  the U.S. Food and Drug Administration said on Tuesday.",
        "date": "05162017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA warns of foot  leg amputations with J&J diabetes drug "
    },
    {
        "content": "Lawyers for five plaintiffs who are seeking to restore a $502 million verdict against Johnson & Johnson over injuries they blamed on its Pinnacle hip implants are arguing that a Texas law that caps punitive damages is unconstitutional.",
        "date": "05152017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Plaintiffs challenge Texas damages cap in J&J hip-implant appeal "
    },
    {
        "content": "Johnson & Johnson is required to add new warnings to its diabetes drug  Invokana  about the risk of foot and leg amputations  the U.S. Food and Drug Administration said on Tuesday.",
        "date": "05172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. FDA warns of foot  leg amputations with J&J diabetes drug "
    },
    {
        "content": "May 16 Johnson & Johnson is required to add new warnings to its diabetes drug  Invokana  about the risk of foot and leg amputations  the U.S. Food and Drug Administration said on Tuesday.",
        "date": "05162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. FDA warns of foot  leg amputations with J&J diabetes drug "
    },
    {
        "content": "* Says Johnson & Johnson has appointed Jane Griffiths as global head of Actelion  to take effect upon closing of transaction",
        "date": "05152017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J appoints Jane Griffiths to head Actelion unit "
    },
    {
        "content": "Johnson & Johnson has agreed to pay more than $400 000 to Oregon to resolve a lawsuit claiming it engaged in a \"phantom recall\" of defective Motrin pills by secretly having supplies bought off shelves to avoid negative publicity.",
        "date": "05112017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J resolves lawsuit by Oregon over 'phantom' Motrin recall "
    },
    {
        "content": "Healthcare conglomerate Johnson & Johnson said on Monday the U.S. Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.",
        "date": "05092017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J discloses U.S. probe related to arthritis drugs "
    },
    {
        "content": "May 8 Healthcare conglomerate Johnson & Johnson said on Monday the U.S. Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.",
        "date": "05082017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J discloses U.S. probe related to arthritis drugs "
    },
    {
        "content": "Johnson & Johnson on Wednesday urged a Missouri appeals court to overturn a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they blamed on her use of the company's talc-based products for genital hygiene.",
        "date": "05102017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J argues appeal of $72 million talc verdict "
    },
    {
        "content": "* J&J says in march 2017  new jersey attorney general division of consumer affairs issued subpoena to janssen pharmaceuticals related to some practices in marketing opioids",
        "date": "05082017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J says in March 2017  New Jersey attorney general division of consumer affairs issued subpoena to Janssen Pharmaceuticals "
    },
    {
        "content": "PARIS Sanofi is currently looking at several external growth opportunities  after having failed to clinch two large deals recently  but feels it has no urgent need to make acquisitions  the drugmaker's chairman told shareholders on Wednesday.",
        "date": "05102017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Sanofi says has no \"absolute need\" to do acquisitions "
    },
    {
        "content": "PARIS Sanofi  is currently looking at several external growth opportunities  after having failed to clinch two large deals recently  but feels it has no urgent need to make acquisitions  the drugmaker's chairman told shareholders on Wednesday.",
        "date": "05102017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Sanofi says has no 'absolute need' to do acquisitions "
    },
    {
        "content": "PARIS  May 10 Sanofi is currently looking at several external growth opportunities  after having failed to clinch two large deals recently  but feels it has no urgent need to make acquisitions  the drugmaker's chairman told shareholders on Wednesday.",
        "date": "05102017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Sanofi says has no \"absolute need\" to do acquisitions "
    },
    {
        "content": "May 4 Johnson & Johnson on Thursday was ordered by a Missouri state court jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.",
        "date": "05042017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J ordered to pay $110 million in talc product liability trial "
    },
    {
        "content": "A federal appeals court on Wednesday sent a case back to a federal judge to reconsider whether to block a former marketing executive at two Johnson & Johnson subsidiaries from joining a rival medical-device maker.",
        "date": "05032017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "11th Circuit vacates order blocking former J&J executive's job with rival "
    },
    {
        "content": "Johnson & Johnson is urging an appeals court to overturn a $151 verdict in favor of five plaintiffs who blamed injuries on its Pinnacle hip implants  saying their lawyer falsely told jurors that two doctors were not compensated to testify as experts.",
        "date": "05042017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J says expert payments doom $151 million hip implant verdict "
    },
    {
        "content": "May 3 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the first trial to flow out of thousands of lawsuits blaming injuries on the blood thinner Xarelto  the drugmakers said on Wednesday.",
        "date": "05032017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bayer  J&J win first product liability trial over Xarelto "
    },
    {
        "content": "Days after a jury in Philadelphia hit Johnson & Johnson with a $20 million verdict in a lawsuit over injuries blamed on a pelvic mesh implant  the company's Ethicon unit is set to face another trial in the city over similar claims.",
        "date": "05052017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J to face another mesh trial after $20 million verdict "
    },
    {
        "content": "A state court jury in Philadelphia has order Johnson & Johnson to pay $20 million to a New Jersey woman who said she suffered injuries after receiving a pelvic mesh implant made by the company's Ethicon unit.",
        "date": "05012017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Ethicon hit with $20 million verdict in mesh case "
    },
    {
        "content": "Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.",
        "date": "05052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J ordered to pay $110 million in U.S. talc-powder trial "
    },
    {
        "content": "May 4 Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.",
        "date": "05052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J ordered to pay $110 million in U.S. talc-powder trial "
    },
    {
        "content": "* Johnson & johnson announces dividend increase of 5.0 percent",
        "date": "04272017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J increase qtrly dividend by 5 pct to $0.84 per share "
    },
    {
        "content": "* Shares rise 2.3 pct (Adds Breakingviews link  updates share price)",
        "date": "04272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 4-Lazard profit beats estimates as deal-making picks up "
    },
    {
        "content": "SAO PAULO Johnson & Johnson   Novartis AG  and Takeda Pharmaceutical Co Ltd  have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA   two people with knowledge of the matter said on Monday.",
        "date": "04242017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J  Takeda among interested in Brazil's Hypermarcas: sources "
    },
    {
        "content": "FRANKFURT Bayer raised its annual core earnings forecast on Thursday after beating expectations with a 15 percent quarterly advance helped by plastics unit Covestro and sales of stroke-prevention pill Xarelto in Europe and Japan.",
        "date": "04272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Stroke drug Xarelto  plastics lift Bayer earnings "
    },
    {
        "content": "SAO PAULO  April 24 Johnson & Johnson  Novartis AG and Takeda Pharmaceutical Co Ltd have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA   two people with knowledge of the matter said on Monday.",
        "date": "04242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 4-J&J  Takeda among interested in Brazil's Hypermarcas  sources say "
    },
    {
        "content": "* Shares up 3 percent to 11 month high (Adds detail on Xarelto  shares  analyst comment)",
        "date": "04272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Stroke drug Xarelto  plastics lift Bayer earnings "
    },
    {
        "content": "SEOUL South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade  the first drug developed by the Samsung Group unit approved in the United States.",
        "date": "04222017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA approves Samsung Bioepis' copy of J&J's Remicade: company "
    },
    {
        "content": "* Earned a bottom-line profit of 375 million Swiss francs ($375.45 million) in Q1 of 2017",
        "date": "04212017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-BB Biotech posts Q1 net profit of 375 million Swiss francs "
    },
    {
        "content": "ZURICH  April 20 The composition of the top Swiss stock index is due to change as early as this month  with Actelion poised to fall out of the Swiss Market Index (SMI) ahead of the completion of the biotechnology company's takeover by Johnson & Johnson.",
        "date": "04202017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J target Actelion could exit Swiss benchmark SMI index this month "
    },
    {
        "content": "SAO PAULO  April 24 Johnson & Johnson  Novartis AG and Takeda Pharmaceutical Co Ltd are in talks with the controlling bloc of Brazilian drugmaker Hypermarcas SA for a buyout  two people with knowledge of the matter said on Monday.",
        "date": "04242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J  Novartis and Takeda in talks for Brazil's Hypermarcas  sources say "
    },
    {
        "content": "* Says Janssen Holding GmbH  a Swiss subsidiary of Johnson & Johnson  published the provisional notice of the end result of its all-cash public tender offer in Switzerland to acquire all publicly held shares of Actelion Ltd",
        "date": "04242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J grabs 92.62 pct Actelion stake in provisional tender results "
    },
    {
        "content": "* Latecomer invested $1.3 bln in biosimilar development so far",
        "date": "04222017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade - company "
    },
    {
        "content": "Johnson & Johnson won the mid-trial dismissal on Monday of a lawsuit by a Pennsylvania man who claimed he developed breasts after taking the antipsychotic drug Risperdal  which is produced by the company's Janssen Pharmaceuticals unit.",
        "date": "04172017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Janssen wins mid-trial dismissal of Risperdal injury case "
    },
    {
        "content": "NEW YORK  April 18 The S&P 500 fell for the fourth time in five sessions on Tuesday  weighed down by declines in Goldman Sachs and Johnson & Johnson following their quarterly results  while geopolitical tensions added to investor caution.",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "US STOCKS SNAPSHOT-Wall St loses ground as Goldman  J&J slump "
    },
    {
        "content": "NEW YORK  April 18 The S&P 500 fell for the fourth time in five sessions on Tuesday  weighed down by a drop in Goldman Sachs and Johnson & Johnson following their quarterly results  while geopolitical tensions added to investor caution.",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-Goldman Sachs  J&J pull Wall Street lower "
    },
    {
        "content": "Cardinal Health Inc said on Tuesday it expected full-year adjusted earnings at the lower end of its forecast  underscoring the U.S. drug distribution industry's struggles with declining generic drug prices.",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Cardinal Health's dull forecast drags along rivals' shares "
    },
    {
        "content": "* Indexes down: Dow 0.69 pct  S&P 0.47 pct  Nasdaq 0.41 pct (Updates to early afternoon)",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-Wall St down as Goldman  J&J's results disappoint "
    },
    {
        "content": "* Shares fall 12 pct; rivals down 5 pct (Adds analyst comments  shares)",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-Cardinal Health's dull forecast drags along rivals' shares "
    },
    {
        "content": "Johnson & Johnson on Tuesday reported disappointing pharmaceutical and consumer product sales as revenue missed analyst estimates  sending its shares sharply lower.",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J first quarter revenue misses estimates; new forecast includes Actelion "
    },
    {
        "content": "April 18 Johnson & Johnson on Tuesday reported disappointing pharmaceutical and consumer product sales as revenue missed analyst estimates  sending its shares sharply lower.",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J 1st qtr revenue misses estimates; new forecast includes Actelion "
    },
    {
        "content": "* Indexes down: Dow 0.49 pct  S&P 0.29 pct  Nasdaq 0.28 pct (Adds details  comments  updates prices)",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-Weak Goldman  J&J results drag down Wall Street "
    },
    {
        "content": "* Indexes down: Dow 0.32 pct  S&P 0.19 pct  Nasdaq 0.14 pct (Updates to open)",
        "date": "04182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-Wall St falls as Goldman  J&J results disappoint "
    },
    {
        "content": "* Phagelux Inc announces collaboration with Johnson & Johnson innovation for new antibacterial solution",
        "date": "04122017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Phagelux announces collaboration with Johnson & Johnson Innovation for new antibacterial solution "
    },
    {
        "content": "Stymied in at least two previous attempts to expose outside investment in mass torts litigation  Johnson & Johnson \u2013 this time alongside Bayer \u2013 is once again asking a court to require plaintiffs to disclose whether litigation funders have an interest in their case.",
        "date": "04112017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Drug companies try again to expose outside investors in mass torts case "
    },
    {
        "content": "ZURICH Swiss billionaire Hansjoerg Wyss has built a nearly 10 percent stake in biotech group Molecular Partners  after share sales by Johnson & Johnson  and other investors  the SIX Swiss Exchange said on Tuesday.",
        "date": "04112017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Swiss billionaire Wyss gets nearly 10 percent of Molecular Partners "
    },
    {
        "content": "Johnson & Johnson urged a judge on Monday to dismiss claims that one of its subsidiary retaliated against a former employee whose whistleblower lawsuit led to an $18 million settlement with the U.S. Justice Department.",
        "date": "04102017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J seeks dismissal of whistleblower's retaliation claims "
    },
    {
        "content": "* Says it entered into a multitarget discovery and optimization collaboration with Janssen Pharmaceuticals  inc  one of the Janssen Pharmaceutical Companies of Johnson & Johnson   on April 7",
        "date": "04072017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-PeptiDream enters into collaboration with Janssen Pharmaceuticals "
    },
    {
        "content": "ZURICH  April 11 Swiss billionaire Hansjoerg Wyss has built a nearly 10 percent stake in biotech group Molecular Partners after share sales by Johnson & Johnson and other investors  the SIX Swiss Exchange said on Tuesday.",
        "date": "04112017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Swiss billionaire Wyss gets nearly 10 pct of Molecular Partners "
    },
    {
        "content": "ZURICH  April 5 Shareholders in Swiss biotech group Actelion approved on Wednesday spinning off its drug discovery and early clinical pipeline into a new company  keeping Johnson & Johnson's $30 billion takeover on track to close in the second quarter.",
        "date": "04052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion shareholders back R&D spinoff  keep J&J deal on track "
    },
    {
        "content": "April 5 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "04052017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "Johnson & Johnson's Janssen Pharmaceuticals has lost an appeal of a ruling that allowed public disclosure of documents the drug company turned over to the city of Chicago as part of an investigation into its marketing of opioid painkillers.",
        "date": "04032017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J loses bid to protect opioid probe records from disclosure "
    },
    {
        "content": "ZURICH Johnson & Johnson  declared its $30 billion tender offer for Swiss biotechnology company Actelion  successful on Friday  reporting it controlled 77.2 percent of the voting rights after the main offer period.",
        "date": "03312017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J declares Actelion tender offer a success  sees closing in second quarter "
    },
    {
        "content": "March 30 Cross-border M&A had its strongest start since 2007  driving first-quarter global volumes up 7 percent  as optimism over U.S. President Donald Trump's economic agenda buoyed the stock market and the dollar  making foreign acquisitions cheaper than some U.S. targets.",
        "date": "03302017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "DEALS-Trump helps make cross-border M&A great again "
    },
    {
        "content": "* Janssen says collaborates with Premier Inc on unique study to improve stroke risk management among hospitalized patients with atrial fibrillation Source text for Eikon: Further company coverage:",
        "date": "04032017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Janssen collaborates with Premier on unique study to improve stroke risk management "
    },
    {
        "content": "ZURICH  March 31 Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday  reporting it controlled 77.2 percent of the voting rights after the main offer period.",
        "date": "03312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J declares Actelion tender offer a success  sees closing in Q2 "
    },
    {
        "content": "* Johnson & Johnson publishes interim result for Actelion tender offer and declares the tender offer successful",
        "date": "03312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson says Janssen Holding to acquire all publicly held shares of Actelion for $280 per share "
    },
    {
        "content": "U.S. healthcare conglomerate Johnson & Johnson  and JPMorgan Chase & Co  became the latest big U.S. companies to suspend all digital advertising on Google's YouTube  over concerns that its ads may have appeared on channels that broadcast offensive videos. |\u00a0Video ",
        "date": "03232017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J  JPMorgan suspend YouTube ads over offensive videos "
    },
    {
        "content": "March 23 U.S. healthcare conglomerate Johnson & Johnson and JPMorgan Chase & Co became the latest big U.S. companies to suspend all digital advertising on Google's YouTube  over concerns that its ads may have appeared on channels that broadcast offensive videos.",
        "date": "03232017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J  JPMorgan suspend YouTube ads over offensive videos "
    },
    {
        "content": "March 23 U.S. healthcare conglomerate Johnson & Johnson became the latest company to suspend all digital advertising on Google's YouTube  over concerns that its ads may have appeared on channels that broadcast offensive videos.",
        "date": "03232017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J latest to suspend ads from YouTube over offensive videos "
    },
    {
        "content": "* Johnson & Johnson - decided to pause all YouTube digital advertising globally",
        "date": "03232017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson says to pause all YouTube digital advertising globally "
    },
    {
        "content": "* J&J -  CEO Alex Gorsky's 2016 total compensation was $26.9 million versus $23.8 million in 2015",
        "date": "03152017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J CEO Alex Gorsky's 2016 total compensation $26.9 mln "
    },
    {
        "content": "A federal appeals court on Thursday revived claims by 12 Minnesota women against Johnson & Johnson\u2019s Mentor Worldwide unit  the former maker of the ObTape transvaginal sling  reversing a lower-court ruling that their lawsuits were filed too late.",
        "date": "03092017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Appeals court revives vaginal sling cases against J&J unit "
    },
    {
        "content": "Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.",
        "date": "03032017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson wins trial in talc product liability lawsuits "
    },
    {
        "content": "Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.",
        "date": "03032017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J wins trial in talc product liability lawsuits "
    },
    {
        "content": "March 3 Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.",
        "date": "03032017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-J&J wins trial in talc product liability lawsuits "
    },
    {
        "content": "March 3 Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the fourth trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.",
        "date": "03032017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J wins fourth trial in talc product liability lawsuits "
    },
    {
        "content": "* New results from second phase 3 study show significant efficacy of guselkumab and superiority versus Humira\u00ae in treatment of moderate to severe plaque psoriasis",
        "date": "03032017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson's Janssen says new results from second phase 3 study show significant efficacy of guselkumab "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  February 28 (Fitch) Fitch Ratings has assigned a 'AAA' rating to  Johnson & Johnson's (JNJ) senior unsecured notes offering. The proceeds will be  used for general corporate purposes. The Rating Outlook is Stable.  KEY RATING DRIVERS Actelion Acquisition: JNJ will acquire Actelion Ltd. (Actelion) for $30 billion  cash. The transaction will be funded using off shore cash. Actelion will spin  off its Research and Development (R&D",
        "date": "02282017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Fitch Rates Johnson & Johnson's Notes Offering 'AAA'; Outlook Stable "
    },
    {
        "content": "* j&j - in february 2017  johnson & johnson received a subpoena from the united states attorney's office for the district of massachusetts",
        "date": "02272017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson says received a subpoena in Feb. from the U.S. attorney's office for the District of Massachusetts "
    },
    {
        "content": "NEW YORK  Feb 27 Johnson & Johnson on Monday said the average list price of its drugs rose less than 10 percent each year since 2012  noting that the net price paid for the drugs  which includes discounts and rebates  was significantly lower.",
        "date": "02272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J says kept drug price increases below 10 pct since 2012 "
    },
    {
        "content": "COPENHAGEN Danish biotech drugmaker Genmab  expects sales of Darzalex  used to fight cancer in bone marrow  to surpass $1 billion this year to become a blockbuster drug  the company said on Wednesday.",
        "date": "02222017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Genmab and J&J's cancer drug set for blockbuster sales this year "
    },
    {
        "content": "COPENHAGEN  Feb 22 Danish biotech drugmaker Genmab expects sales of Darzalex  used to fight cancer in bone marrow  to surpass $1 billion this year to become a blockbuster drug  the company said on Wednesday.",
        "date": "02222017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Genmab and J&J's cancer drug set for blockbuster sales this year "
    },
    {
        "content": "COPENHAGEN  Feb 22 Danish biotech drugmaker Genmab expects sales of Darzalex  used to fight cancer in bone marrow  to surpass $1 billion this year to become a blockbuster drug  the company said on Wednesday.",
        "date": "02222017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-Genmab and J&J's cancer drug set for blockbuster sales this year "
    },
    {
        "content": "COPENHAGEN  Feb 22 Danish biotech drugmaker Genmab's Darzalex  which is used to fight cancer in bone marrow and marketed by Johnson & Johnson  has the potential to achieve annual peak annual sales as high as $13 billion  its chief executive told Reuters.",
        "date": "02222017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Genmab's Darzalex could achieve peak annual sales of $9 bln -CEO "
    },
    {
        "content": "BRUSSELS  Feb 20 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "02202017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "EU mergers and takeovers (Feb 20) "
    },
    {
        "content": "ZURICH Swiss biotech company Actelion   days before agreeing to a $30 billion bid by Johnson & Johnson   found a rival offer to be as attractive but went with J&J because its offer provided more certainty  a filing showed on Thursday.",
        "date": "02162017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "How Sanofi lost out to J&J in $30 billion battle for Actelion "
    },
    {
        "content": "* J&J's $280 per share tender offer to start March 3   (Recasts with rival offer  adds background throughout)",
        "date": "02162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-How Sanofi lost out to J&J in $30 bln battle for Actelion "
    },
    {
        "content": "* Swiss Takeover Commission says J&J offer for Actelion meets legal requirements  Source text for Eikon:  Further company coverage:    (Reporting By Zurich newsroom)",
        "date": "02162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Swiss Takeover Commission OKs J&J offer for Actelion "
    },
    {
        "content": "ZURICH  Feb 16 Actelion said on Thursday that Johnson & Johnson's agreed tender offer for the Swiss biotechnology company's shares is expected to start on March 3 and run until March 30.",
        "date": "02162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Actelion says J&J's $280 per share offer to start March 3 "
    },
    {
        "content": "ZURICH  Feb 16 Actelion said on Thursday that Johnson & Johnson's agreed tender offer for the Swiss biotechnology company's shares is expected to start on March 3 and to run to March 30.",
        "date": "02162017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion says J&J's $280 per share offer to start March 3 "
    },
    {
        "content": "Medical device maker Integra LifeSciences Holdings Corp said it would buy Johnson & Johnson's Codman neurosurgery business for $1.05 billion in cash  to expand its presence outside the United States.",
        "date": "02152017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Integra to buy J&J's Codman neurosurgery business for $1.05 billion "
    },
    {
        "content": "* Integra stock up as much as 6 pct  J&J marginally up   (Adds details from the conference call  J&J comment  shares)",
        "date": "02152017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-Integra to buy J&J's Codman neurosurgery business for $1.05 bln "
    },
    {
        "content": "* Integra Lifesciences plans to acquire the Codman neurosurgery business from Johnson & Johnson for $1.045 billion in cash",
        "date": "02152017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson for $1.045 bln "
    },
    {
        "content": "ZURICH Swiss drugmaker Actelion's  2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH)  it said on Tuesday.",
        "date": "02142017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Actelion  being bought by J&J  says full year core net income rose 27 percent "
    },
    {
        "content": "Feb 15 Integra LifeSciences Holdings Corp  said it has made an offer to buy Johnson & Johnson's  Codman neurosurgery business for $1.05 billion in cash.",
        "date": "02152017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Integra offers to buy J&J's Codman neurosurgery business "
    },
    {
        "content": "ZURICH  Feb 14 Swiss drugmaker Actelion's  2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH)  it said on Tuesday.",
        "date": "02142017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Actelion  being bought by J&J  says FY core net income rose 27 pct "
    },
    {
        "content": "FRANKFURT  Feb 8 Bayer's best-selling blood-thinning drug Xarelto has also proved effective in preventing heart attacks and strokes in patients suffering from certain types of artery disease  the company said on Wednesday.",
        "date": "02082017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Bayer's blood thinner also effective for artery disease "
    },
    {
        "content": "LONDON  Feb 8 GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle.",
        "date": "02082017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "GlaxoSmithKline and Gilead to face off at HIV meeting next week "
    },
    {
        "content": "U.S. biopharmaceutical company Tesaro Inc  is discussing its options with investment banks after receiving acquisition interest from several drugmakers  according to people familiar with the matter.",
        "date": "02082017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources "
    },
    {
        "content": "* State Street Corp reports a 5.65 percent passive stake in Johnson & Johnson  as of dec. 31  2016  Source text: (http://bit.ly/2kD1FeM) Further company coverage:",
        "date": "02072017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-State Street Corp reports a 5.65 pct passive stake in Johnson & Johnson  as of Dec. 31 "
    },
    {
        "content": "Johnson & Johnson and its DePuy unit have asked a federal appeals court to throw out a $151 million bellwether verdict in multidistrict litigation alleging its Pinnacle metal-on-metal hip implants are defective.",
        "date": "02022017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J asks appeals court to toss $151 million Pinnacle verdict "
    },
    {
        "content": "* ChemDiv-Entered into hit identification collaboration with Janssen to identify potent hit series for range of targets across multiple therapeutic areas",
        "date": "01312017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-ChemDiv announces multi-year hit identification collaboration with Janssen "
    },
    {
        "content": "LONDON Mergers and acquisitions (M&A) activity in Europe  the Middle East and Africa (EMEA) hit an 11-year high in January  boosted by several huge deals  Thomson Reuters data on Tuesday showed.",
        "date": "01312017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "European M&A activity hit 11-year high in January "
    },
    {
        "content": "* Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable  Source text for Eikon:  Further company coverage:",
        "date": "01272017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable "
    },
    {
        "content": "Jan 27 The Missouri Supreme Court has denied Johnson & Johnson's bid to move out of a St. Louis state court thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.",
        "date": "01272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J loses venue fight for talc lawsuits in Missouri "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  January 27 (Fitch) Fitch Ratings has affirmed Johnson & Johnson's (JNJ)  Issuer Default Rating at 'AAA'. The Rating Outlook is Stable. A complete list of  Fitch's rating actions follow at the end of this press release. KEY RATING DRIVERS The rating action follows JNJ's announcement that it will acquire Actelion Ltd.  (Actelion) for $30 billion cash. Actelion will spin off its Research and  Development (R&D) business as a separa",
        "date": "01272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Fitch Affirms Johnson & Johnson's IDR at 'AAA'; Outlook Stable "
    },
    {
        "content": "NEW YORK The dollar rose against the yen on Friday  extending a broad trend that has been in place since U.S. President Donald Trump's election in November on expectations of more pro-growth policies to bolster an economy that has improved but sputtered at times.",
        "date": "01272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. dollar continues Trump-related broad uptrend "
    },
    {
        "content": "LONDON  Jan 27 The dollar recovered more ground against a basket of currencies on Friday  catching up with rises in U.S. stock markets and bond yields as the trade on U.S. President Donald Trump's growth policies moved back to pole position in investors' thinking.",
        "date": "01272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FOREX-Dollar heads for flat week as inflation trade revives "
    },
    {
        "content": "* Mexico tax comments puts focus back on dollar-friendly policy",
        "date": "01272017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FOREX-Dollar climbs more after Trump's Mexico comments "
    },
    {
        "content": "NEW YORK Johnson & Johnson's  chief executive officer said on Tuesday that responsible drug pricing is a priority and discussed changes he would like to see on the U.S. tax code and healthcare policy  one day after meeting with President Donald Trump.",
        "date": "01242017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson plans more price transparency; eyes U.S. tax  healthcare changes "
    },
    {
        "content": "Johnson & Johnson's chief executive officer said on Tuesday that responsible drug pricing is a priority and discussed changes he would like to see on the U.S. tax code and healthcare policy  one day after meeting with President Donald Trump.",
        "date": "01242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J plans more price transparency; eyes U.S. tax  healthcare changes "
    },
    {
        "content": "ALLSCHWIL  Switzerland U.S. healthcare giant Johnson & Johnson  will buy Swiss biotech company Actelion  in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline  the companies said on Thursday. |\u00a0Video ",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson refills drug cabinet with $30 billion Actelion deal "
    },
    {
        "content": "NEW YORK  Jan 24 Johnson & Johnson's  chief executive officer said on Tuesday that responsible drug pricing is a priority and discussed changes he would like to see on the U.S. tax code and healthcare policy  one day after meeting with President Donald Trump.",
        "date": "01242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J plans more price transparency; eyes U.S. tax  healthcare changes "
    },
    {
        "content": "* Oil up on stock market  but U.S. supply caps gains   (Updates to U.S. market close)",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "GLOBAL MARKETS-Stocks near record high  dollar up on optimism  earnings "
    },
    {
        "content": "* Q4 adjusted non-GAAP earnings per share $1.58 excluding items",
        "date": "01242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson reports Q4 adj. earnings $1.58 per share "
    },
    {
        "content": "Many shareholders \u00a0of Europe\u2019s biggest biotech company  Actelion  got good news when Johnson & Johnson announced it $30 billion takeover. But hedge fund managers weren't the only ones clinking glasses: \u00a0individual investors  like the 70-year-old son of a Swiss butcher  were among the top winners in the largest pharma deal in Europe in 13 years.",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BUSINESS WATCH - Stranded at sea "
    },
    {
        "content": "Jan 24 Johnson & Johnson reported a 1.7 percent rise in fourth-quarter sales  due to a strong demand for its newer products.",
        "date": "01242017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J Q4 sales up 1.7 pct  plans to divest diabetes care division "
    },
    {
        "content": "* Oil up on stock market  but U.S. supply caps gains   (Updates to U.S. market open  adds details  changes dateline  previous LONDON)",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "GLOBAL MARKETS-Stocks near record highs  dollar up on optimism  earnings "
    },
    {
        "content": "* But results at Daily Mail  Unilever disappoint   (Adds details  closing prices)",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "M&A boost helps European shares stay at one-year high "
    },
    {
        "content": "LONDON  Jan 26 Advisers could pocket up to $100 million in fees from Johnson & Johnson's $30 billion acquisition of Swiss biotech firm Actelion  the largest takeover of a European healthcare business in more than a decade.",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Advisers could land $100 million payday from Actelion sale "
    },
    {
        "content": "* Shares pare losses after falling more than 1 pct   (Releads  adds analyst reactions  updates shares)",
        "date": "01232017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "UPDATE 3-Actelion drug setback unlikely to derail J&J talks - analysts "
    },
    {
        "content": "* Investors growing impatient after it fails to land acquisitions",
        "date": "01202017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "INSIGHT-Sanofi's M&A misses frustrate some investors in drugmaker "
    },
    {
        "content": "New multidistrict litigation over claims that a Sanofi breast cancer drug causes permanent hair loss more than doubled in size over the past month  and plaintiffs are continuing to mount ovarian cancer claims involving Johnson & Johnson's talc products in federal court.",
        "date": "01192017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "MDL Watch: Sanofi Taxotere  Bair Hugger and J&J talc cases grow "
    },
    {
        "content": "* J&J says on investor call it has two year agreement not to sell on the open market any equity stake in actelion research and development unit",
        "date": "01262017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J has two-year agreement on stake in R&D company "
    },
    {
        "content": "* Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31  2016 - SEC filing  Source text: (http://bit.ly/2j9ZI8k) Further company coverage:",
        "date": "01182017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31  2016 "
    },
    {
        "content": "Johnson & Johnson will have to face a retrial of patent infringement claims over contact lens technology after the U.S. Supreme Court on Tuesday refused to review a lower court's decision overturning the company's win at an earlier trial.",
        "date": "01172017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "U.S. Supreme Court declines to hear J&J contact lens patent dispute "
    },
    {
        "content": "BRUSSELS  Jan 18 The following are mergers under review by the European Commission and a brief guide to the EU merger process:",
        "date": "01182017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "EU mergers and takeovers (Jan 18) "
    },
    {
        "content": "Two Johnson & Johnson units have asked a U.S. appeals court to uphold a ruling that blocked a former longtime executive from taking a high-profile role at a rival medical device maker  saying her defection poses an imminent risk to the companies.",
        "date": "01172017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "11th Circuit asked to block former J&J executive's job with rival "
    },
    {
        "content": "* Orthocell announces collaboration with Johnson & Johnson Innovation",
        "date": "01122017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Orthocell announces collaboration with Johnson & Johnson "
    },
    {
        "content": "* Takeda able to limit debt  retain credit rating post Ariad deal-CFO",
        "date": "01102017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal "
    },
    {
        "content": "A U.S. judge almost halved the award in a December jury verdict that ordered Johnson & Johnson  and its DePuy Orthopaedics unit to pay more than $1 billion to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants.",
        "date": "01042017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Judge halves $1 billion award in J&J hip implants case "
    },
    {
        "content": "ZURICH Johnson & Johnson  and Actelion  have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm  newspaper Tages-Anzeiger reported on Friday  without saying how it got the information.",
        "date": "01062017",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J  Actelion approach Swiss takeover board over deal structure: paper "
    },
    {
        "content": "ZURICH  Jan 6 The Swiss blue-chip SMI  was seen opening 0.3 percent higher at 8413 points on Friday  according to premarket indications by bank Julius Baer .",
        "date": "01062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Swiss stocks - Factors to watch on Jan 5 "
    },
    {
        "content": "ZURICH  Jan 6 Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm  newspaper Tages-Anzeiger reported on Friday  without saying how it got the information.",
        "date": "01062017",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J  Actelion approach Swiss takeover board over deal structure -paper "
    },
    {
        "content": "Johnson & Johnson  is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd  that would separate its commercialized portfolio from its research and development assets  people familiar with the matter said on Thursday.",
        "date": "12292016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Exclusive: J&J discussing breaking up Actelion in an acquisition - sources "
    },
    {
        "content": "ZURICH/FRANKFURT Swiss biotech company Actelion  has turned back to prospective bidder Johnson & Johnson  for exclusive talks about a \"strategic transaction\"  in an about-turn that appears to sideline rival suitor Sanofi . |\u00a0Video ",
        "date": "12222016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Actelion re-enters talks with J&J  sidelining Sanofi "
    },
    {
        "content": "A late-stage trial found that continuing treatment with Pfizer Inc's cancer drug Xtandi in addition to a regimen of Zytiga and a steroid worked no better than the two other drugs alone in patients with advanced prostate cancer whose disease had worsened  the company said on Wednesday.",
        "date": "12142016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Pfizer's Xtandi fails in progression trial vs. J&J's Zytiga "
    },
    {
        "content": "ZURICH/LONDON Switzerland's Actelion Ltd  is in talks with French drugmaker Sanofi  about a deal  sources said on Wednesday  after U.S. healthcare group Johnson & Johnson  abandoned efforts to buy the company. |\u00a0Video ",
        "date": "12142016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion talking to Sanofi after J&J exit "
    },
    {
        "content": "NEW YORK Johnson & Johnson  shares could rally about 20 percent to the mid-$130s as operating improvements spur earnings growth  Barron's said in a report.",
        "date": "12112016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson shares could rally about 20 percent: Barron's "
    },
    {
        "content": "Johnson & Johnson  will challenge the fairness of a trial that produced a verdict of $1 billion in damages against the company last week over allegations of design flaws in its  Pinnacle hip implant.",
        "date": "12072016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J questions fairness of hip implant trial  $1 billion verdict "
    },
    {
        "content": "LONDON A top-30 investor in Swiss pharmaceutical company Actelion  said he would back a takeover approach for the whole company from U.S. rival Johnson & Johnson  above 246 Swiss francs.",
        "date": "12062016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Top Actelion shareholder says backs J&J deal above 246 Sfr/share "
    },
    {
        "content": "U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.",
        "date": "12062016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Trump's corporate tax holiday could spur pharma M&A "
    },
    {
        "content": "French drugmaker Sanofi  is considering a bid for Swiss biotech company Actelion   rivaling an offer made by U.S. healthcare company Johnson & Johnson   Bloomberg reported.",
        "date": "12062016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Sanofi exploring bid for Actelion amid J&J talks: Bloomberg "
    },
    {
        "content": "ZURICH Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm  betting that Johnson & Johnson's (J&J)  approach will result in an outright takeover and handsome returns.",
        "date": "12022016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Actelion's silence has hedge funds betting big on J&J deal "
    },
    {
        "content": "A federal jury in Dallas on Thursday ordered Johnson & Johnson  and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.",
        "date": "12022016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson hit with over $1 billion verdict on hip implants "
    },
    {
        "content": "ZURICH Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.",
        "date": "11302016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Actelion shares fall on report it rejects J&J offer "
    },
    {
        "content": "ZURICH/LONDON Some Actelion shareholders would be attracted by a $27 billion bid for the Swiss biotech company from Johnson & Johnson  leaving Chief Executive Jean-Paul Clozel with some explaining to do if he turned down an offer around that level.",
        "date": "11302016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Rejecting J&J could leave Actelion with 'lot of explaining to do' "
    },
    {
        "content": "ZURICH  Nov 28 Actelion Chief Executive Jean-Paul Clozel's desire to keep Europe's biggest biotech company independent after building it from scratch  means Johnson & Johnson will have to pay a steep premium if a takeover is to succeed.",
        "date": "11282016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion's ambitious independent-minded CEO will drive up takeover price "
    },
    {
        "content": "Nov 29 The following bids  mergers  acquisitions and disposals were reported by 2100 GMT on Tuesday:",
        "date": "11292016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "LONDON U.S. healthcare company Johnson & Johnson has raised its offer for Actelion  a source told Reuters on Tuesday  stepping up pressure on the Swiss biotech firm to accept a takeover deal.",
        "date": "11292016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J raises Actelion takeover pressure with higher price: source "
    },
    {
        "content": "ZURICH Shares in Swiss biotech company Actelion  plunged on Tuesday after a report the company was not actively considering selling itself  but instead weighing a \"complicated deal\" to link with U.S. healthcare giant Johnson & Johnson .",
        "date": "11292016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion shares plunge on report it eyes 'complicated' J&J deal "
    },
    {
        "content": "ZURICH  Nov 29 Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself  but instead weighing a \"complicated deal\" to link with U.S. healthcare giant Johnson & Johnson.",
        "date": "11292016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion shares plunge on report it eyes \"complicated\" J&J deal "
    },
    {
        "content": "Nov 29 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.",
        "date": "11292016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "PRESS DIGEST- Financial Times - Nov 29 "
    },
    {
        "content": "ZURICH/FRANKFURT U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm  currently valued at about $20 billion.",
        "date": "11262016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Biotech group Actelion  Johnson & Johnson confirm deal talks "
    },
    {
        "content": "ZURICH/FRANKFURT U.S. healthcare company Johnson & Johnson  said on Friday it was in preliminary talks with Actelion  about a potential takeover of Europe's largest biotech firm  currently valued at about $20 billion.",
        "date": "11262016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson approaches Actelion about takeover deal "
    },
    {
        "content": "* Johnson & Johnson confirms discussions with Actelion regarding potential transaction",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J confirms discussions with Actelion regarding potential deal "
    },
    {
        "content": "Nov 24 U.S. healthcare company Johnson & Johnson  has approached Swiss biotechnology firm Actelion Ltd  about a potential takeover  Bloomberg reported on Thursday  citing people it said were familiar with the matter.",
        "date": "11242016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J makes takeover approach for Swiss drugmaker Actelion -Bloomberg "
    },
    {
        "content": "ZURICH/FRANKFURT  Nov 25 U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm  currently valued at about $20 billion.",
        "date": "11262016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 4-Johnson & Johnson approaches Actelion about takeover deal "
    },
    {
        "content": "ZURICH  Nov 25 Actelion has confirmed it has been approached by Johnson & Johnson about a possible transaction to take over the Swiss drugmaker.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion confirms Johnson & Johnson approach "
    },
    {
        "content": "ZURICH/FRANKFURT  Nov 25 Shares in Actelion Ltd  jumped as much as 19 percent to record highs on Friday on reports that U.S. healthcare company Johnson & Johnson  was interested in a takeover of the fast-growing Swiss biotechnology firm.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Actelion shares surge on reported J&J takeover approach "
    },
    {
        "content": "LONDON  Nov 25 European shares edged higher on Friday  heading for their third straight week of gains  with drugmakers leading the market after Swiss biotechnology firm Actelion surged on a report of a takeover approach by Johnson & Johnson.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "European shares head for 3rd week of gains  Actelion leads "
    },
    {
        "content": "U.S. healthcare company Johnson & Johnson has approached Swiss biotechnology firm Actelion Ltd about a potential takeover  Bloomberg reported on Thursday  citing people it said were familiar with the matter.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg "
    },
    {
        "content": "LONDON  Nov 25 European shares edged lower in early trading on Friday  with weaker oil prices hurting energy stocks and Italian lenders dragging down European banking index.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "European shares edge lower but head for 3rd week of gains "
    },
    {
        "content": "Nov 25 U.S. healthcare company Johnson & Johnson  has approached Swiss biotechnology firm Actelion Ltd  about a potential takeover  Bloomberg reported on Thursday  citing people it said were familiar with the matter.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J makes takeover approach for Swiss drugmaker Actelion - Bloomberg "
    },
    {
        "content": "LONDON A costly blood cancer pill sold in Europe by Johnson & Johnson will be made routinely available to certain patients in Britain with chronic lymphocytic leukemia  after the U.S. company agreed to cut the price.",
        "date": "11252016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Costly leukemia pill wins UK green light after price cut "
    },
    {
        "content": "* Paulson & Co cuts share stake in Alexion Pharmaceuticals Inc by 15.0 percent to 227 700 shares",
        "date": "11142016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Paulson & Co cuts share stake in Alexion Pharmaceuticals  Johnson & Johnson "
    },
    {
        "content": "* British artificial intelligence firm announces exclusive license agreement with Janssen for clinical stage drug candidates  facilitated by Johnson & Johnson innovation",
        "date": "11082016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-British artificial intelligence firm announces license agreement with Janssen "
    },
    {
        "content": "After a $67.5 million jury verdict against Johnson & Johnson on Oct. 27 marked its third straight trial defeat in an onslaught of lawsuits claiming its talc-based products cause ovarian cancer  the company is hoping to reverse the trend by having the cases heard in a different court.",
        "date": "11072016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Analysis: After $195 mln in talc verdicts  J&J strives to change court "
    },
    {
        "content": "After a $67.5 million jury verdict against Johnson & Johnson  on Oct. 27 marked its third straight trial defeat in an onslaught of lawsuits claiming its talc-based products cause ovarian cancer  the company is hoping to reverse the trend by having the cases heard in a different court.",
        "date": "11062016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "After $195 million in talc verdicts  J&J strives to change court "
    },
    {
        "content": "CHICAGO  Nov 9 An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped  marking yet another step toward the development of a so-called functional cure for HIV.",
        "date": "11092016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J vaccine plus Gilead immune booster shows promise as HIV fighter "
    },
    {
        "content": "Booming pharmaceutical sales drove strong quarterly results for Johnson & Johnson   but the company's shares fell more than 2 percent on worries that its blockbuster Remicade arthritis drug would soon face cheaper competition.",
        "date": "10182016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J shares lose ground on fears of Pfizer's answer to Remicade "
    },
    {
        "content": "* U.S. Remicade sales rise 9.4 pct   (Adds analyst comments  updates shares)",
        "date": "10182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 4-J&J shares lose ground on fears of Pfizer's answer to Remicade "
    },
    {
        "content": "* U.S. Remicade sales rise 9.4 pct   (Adds CFO comment  context on Remicade patent battle with Pfizer)",
        "date": "10182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J says pharma future bright  despite threat to Remicade "
    },
    {
        "content": "BOSTON (Due to inaccurate data in Fidelity's original filing  this October 5 story corrects to show that Fidelity's venture arm's investment in Adaptimmune rose to $41 million  not $270 million; that Fidelity Select Biotechnology Portfolio paid at least four times more than rivals for shares  not 24 times; and that the venture arm got its Adaptimmune shares for about $3.54 each  not 59 cents each.)",
        "date": "10132016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Special Report: How Fidelity's owners get richer at everyday investors' expense "
    },
    {
        "content": "Pfizer Inc  said on Monday it will begin shipping its biosimilar version of Johnson & Johnson's  blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent discount to current wholesale prices.",
        "date": "10172016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Pfizer to start shipping biosimilar version of J&J's Remicade in November "
    },
    {
        "content": "Oct 18 U.S. stock index futures were modestly higher on Tuesday  buoyed by better-than-expected quarterly reports  including from Netflix and Johnson & Johnson.",
        "date": "10182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-Futures up on strong reports from Netflix  J&J "
    },
    {
        "content": "* Q3 earnings per share view $1.66 -- Thomson Reuters I/B/E/S",
        "date": "10182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson reports Q3 EPS $1.53 "
    },
    {
        "content": " ",
        "date": "10132016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "How Fidelity's owners get richer at everyday investors' expense "
    },
    {
        "content": "Oct 17 Pfizer Inc said on Monday it plans to begin shipping its biosimilar version of Johnson & Johnson's blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent discount to current wholesale prices.",
        "date": "10172016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Pfizer set to start shipping Remicade biosimilar next month "
    },
    {
        "content": "Oct 18 Johnson & Johnson reported a 4.2 percent increase in quarterly revenue  fueled by strong sales in its prescription drugs business.",
        "date": "10182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J quarterly sales rise 4.2 pct "
    },
    {
        "content": "Johnson & Johnson is telling patients that it has learned of a security vulnerability in one of its insulin pumps that a hacker could exploit to overdose diabetic patients with insulin  though it describes the risk as low. |\u00a0Video ",
        "date": "10042016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J warns diabetic patients: Insulin pump vulnerable to hacking "
    },
    {
        "content": "FRANKFURT  Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee  Johnson & Johnson unit  Jenssen  reported positive results from a phase 3 study of psoriasis drug guselkumab.",
        "date": "10012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Morphosys moves closer to getting first antibody drug on market "
    },
    {
        "content": "Oct 4 Johnson & Johnson is telling patients that it has learned of a security vulnerability in one of its insulin pumps that a hacker could exploit to overdose diabetic patients with insulin  though it describes the risk as low.",
        "date": "10042016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J warns diabetic patients: Insulin pump vulnerable to hacking "
    },
    {
        "content": "The following is the text of a letter mailed to patients on Monday by Johnson & Johnson's Animas diabetes unit describing a cyber security vulnerability in its Animas OneTouch Ping insulin pump:",
        "date": "10042016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson letter on cyber bug in insulin pump "
    },
    {
        "content": "ZURICH Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear  the Swiss drugmaker said on Saturday  citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.",
        "date": "10012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Novartis psoriasis drug maintains efficacy after four years: study "
    },
    {
        "content": "ZURICH  Oct 1 Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear  the Swiss drugmaker said on Saturday  citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson .",
        "date": "10012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Novartis psoriasis drug maintains efficacy after 4 years - study "
    },
    {
        "content": "Sept 26 Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug  Stelara  for use in adults with Crohn's disease.",
        "date": "09262016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FDA approves J&J's autoimmune drug Stelara for Crohn's disease "
    },
    {
        "content": "Abbott Laboratories  said it would sell its eye care business to Johnson & Johnson  for\u00a0about $4.33 billion\u00a0in cash to focus on cardiovascular devices and diagnostics business.",
        "date": "09162016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Abbott to sell its eye care business to J&J for about $4.33 billion "
    },
    {
        "content": "Sept 16 Abbott Laboratories said it would sell its eye care business to Johnson & Johnson  for about $4.33 billion in cash to focus on cardiovascular devices and diagnostics business.",
        "date": "09162016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-Abbott to sell its eye care business to J&J for about $4.33 bln "
    },
    {
        "content": "* Net impact of this transaction is not expected to impact Abbott's overall targeted ongoing earnings per share in 2017.",
        "date": "09162016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 bln "
    },
    {
        "content": "* Johnson & Johnson announces agreement to acquire Abbott Medical Optics",
        "date": "09162016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson to buy Abbott Medical Optics for $4.325 bln "
    },
    {
        "content": "Sept 16 Abbott Laboratories is in talks to sell its eye-surgery business to Johnson & Johnson  the Wall Street Journal reported  citing sources familiar with the matter.",
        "date": "09162016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Abbott in talks to sell its eye-surgery business to J&J - WSJ "
    },
    {
        "content": "Aug 22 Pfizer Inc  beating out numerous other bidders  said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash  adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.",
        "date": "08222016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal "
    },
    {
        "content": "* Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16   Source text (http://bit.ly/2biMrcb) Further company coverage:",
        "date": "08192016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing "
    },
    {
        "content": "* Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing",
        "date": "08172016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson announces ruling related to Remicade "
    },
    {
        "content": "* Ups share stake in Valeant Pharmaceuticals International Inc by 43.6 pct to 19.1 mln shares - SEC filing",
        "date": "08152016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Paulson & Co raises share stake in Valeant  Facebook - SEC filing "
    },
    {
        "content": "July 29 AbbVie Inc posted higher-than-expected quarterly profit and revenue  driven by demand for its flagship drug Humira  and raised its earnings forecast for the year.",
        "date": "07292016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Drugmaker AbbVie bumps up profit forecast on strong Humira sales "
    },
    {
        "content": "* Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer",
        "date": "07262016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research "
    },
    {
        "content": "A federal judicial panel has been asked to consolidate nearly a dozen lawsuits filed in U.S. federal courts alleging Johnson & Johnson failed to warn women that using its talc-based powders for feminine hygiene could increase their risk of ovarian cancer.",
        "date": "07202016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "New MDL sought for cases over J&J talc powder and ovarian cancer "
    },
    {
        "content": "Two former executives of Acclarent Inc  a medical device company bought by Johnson & Johnson in 2010  were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use.",
        "date": "07202016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J unit's former executives convicted of unapproved marketing "
    },
    {
        "content": "July 19 Two former executives of Acclarent Inc  a medical device company bought by Johnson & Johnson in 2010  were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use.",
        "date": "07202016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J unit's former execs convicted of unapproved marketing "
    },
    {
        "content": "Johnson & Johnson  on Tuesday raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat  estimates  helped by strength in its prescription drugs business.",
        "date": "07192016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson raises 2016 forecast  shares touch record high "
    },
    {
        "content": "* Johnson & Johnson announces completion of acquisition of Vogue International Llc  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "07182016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson announces completion of Vogue International deal "
    },
    {
        "content": "July 19 Johnson & Johnson on Tuesday raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat  estimates  helped by strength in its prescription drugs business.",
        "date": "07192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 4-Johnson & Johnson raises 2016 forecast  shares touch record high "
    },
    {
        "content": "July 18 TPG Capital LP  one of the world's largest private equity firms  has agreed to acquire Beaver-Visitec International  a U.S. maker of tools used in eye surgery  from buyout firm RoundTable Capital Partners.",
        "date": "07182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "TPG to acquire surgical tools maker Beaver-Visitec "
    },
    {
        "content": "* Q2 earnings per share view $1.68 -- Thomson Reuters I/B/E/S",
        "date": "07192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson posts Q2 earnings of $1.43/share "
    },
    {
        "content": "* Sets quarterly cash dividend of $0.80 per share  Source text for Eikon:  Further company coverage:",
        "date": "07182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson sets quarterly cash dividend of $0.80 per share "
    },
    {
        "content": "July 19 Diversified healthcare company Johnson & Johnson reported a 3.9 percent increase in second-quarter sales  helped by strength in its pharmaceuticals business.",
        "date": "07192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J quarterly sales rise 3.9 pct "
    },
    {
        "content": "* Johnson & Johnson to buy 20 pct of Japanese cosmetics maker - Nikkei",
        "date": "07112016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson to buy 20 pct stake in CI:Z Holdings Co - Nikkei "
    },
    {
        "content": "NEW YORK  July 8 Shares of many U.S. companies that produce prescription medicines have been under pressure this year  but the picture has been rosier for makers of pacemakers  knee replacements and other medical devices.",
        "date": "07082016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Medtech's 2016 stock surge confronts second-quarter test "
    },
    {
        "content": "NEW YORK A U.S. jury on Friday awarded $70 million to the family of a boy who developed breasts after taking Johnson & Johnson unit Janssen Pharmaceuticals' antipsychotic drug Risperdal.",
        "date": "07012016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Janssen hit with $70 million verdict in Risperdal trial "
    },
    {
        "content": "NEW YORK A U.S. jury on Friday awarded $70 million to the family of a boy who developed breasts after taking Johnson & Johnson unit Janssen Pharmaceuticals' antipsychotic drug Risperdal.",
        "date": "07012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's Janssen hit with $70 mln verdict in Risperdal trial "
    },
    {
        "content": "NEW YORK  July 1 A U.S. jury on Friday awarded $70 million to the family of a boy who developed breasts after taking Johnson & Johnson unit Janssen Pharmaceuticals' antipsychotic drug Risperdal.",
        "date": "07012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-J&J's Janssen hit with $70 mln verdict in Risperdal trial "
    },
    {
        "content": "July 1 A U.S. jury on Friday awarded $70 million to the family of a boy who developed breasts after taking Johnson & Johnson unit Janssen Pharmaceuticals' antipsychotic drug Risperdal  lawyers for the family said.",
        "date": "07012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's Janssen hit with $70 mln verdict in Risperdal trial -lawyers "
    },
    {
        "content": "NEW YORK  July 6 A U.S. judge has slashed a $500 million verdict against Johnson & Johnson and its DePuy unit over allegedly defective metal-on-metal Pinnacle hip implants to approximately $151 million.",
        "date": "07062016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. judge cuts $500 mln verdict over J&J hip implants "
    },
    {
        "content": "NEW YORK A U.S. judge has slashed a $500 million verdict against Johnson & Johnson and its DePuy unit over allegedly defective metal-on-metal Pinnacle hip implants to approximately $151 million.",
        "date": "07062016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. judge cuts $500 million verdict over J&J hip implants "
    },
    {
        "content": "* Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable  Source text for Eikon:  Further company coverage:",
        "date": "06302016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  June 30 (Fitch) Fitch Ratings has affirmed Johnson & Johnson's (JNJ)  Issuer Default Rating at 'AAA'. The Rating Outlook is Stable. A complete list of  Fitch's rating actions follow at the end of this press release. KEY RATING DRIVERS The company's 'AAA' rating reflects the following: --Potential biosimilar competition for Remicade in the U.S. in  late-2016/early-2017 and adverse foreign exchange movement will weigh on  revenue",
        "date": "06302016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Fitch Affirms Johnson & Johnson's IDR at 'AAA'; Outlook Stable "
    },
    {
        "content": "Johnson & Johnson and its DePuy Orthopaedics unit have asked a federal appeals court to halt an upcoming bellwether trial over their Pinnacle metal-on-metal hip implants until their challenges to a previous $502 million verdict are resolved.",
        "date": "06242016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J asks 5th Circuit to delay next Pinnacle hip bellwether trial "
    },
    {
        "content": "Johnson & Johnson has filed a second patent lawsuit against South Korean drug maker Celltrion Inc and Pfizer Inc's Hospira unit to stop them from launching a cheaper version of J&J's arthritis and inflammatory bowel drug Remicade in the U.S.",
        "date": "06162016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J files new lawsuit to block biosimilar version of Remicade "
    },
    {
        "content": "* Amyris announces collaboration with Johnson & Johnson innovation for biosynthetic drug discovery",
        "date": "06062016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Amyris announces collaboration with Johnson & Johnson Innovation "
    },
    {
        "content": "June 5 Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer  according to research the company hopes will pave the way for wider use of the treatment.",
        "date": "06052016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J myeloma drug  in combo regimen  delays worsening of the disease "
    },
    {
        "content": "Johnson & Johnson  said on Thursday it would acquire Vogue International for $3.3 billion  adding brands such as OGX shampoos and FX hair styling products to its consumer portfolio that includes Neutrogena and Clean & Clear.",
        "date": "06022016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J to buy hair care products maker Vogue for $3.3 billion "
    },
    {
        "content": "June 2 Johnson & Johnson said on Thursday it would acquire Vogue International for $3.3 billion  adding brands such as OGX shampoos and FX hair styling products to its consumer portfolio that includes Neutrogena and Clean & Clear.",
        "date": "06022016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J to buy hair care products maker Vogue for $3.3 bln "
    },
    {
        "content": "June 2 Johnson & Johnson said on Thursday it would acquire Vogue International  a privately held hair care and personal care products maker  for about $3.3 billion in cash.",
        "date": "06022016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J to buy hair care products maker Vogue for $3.3 bln "
    },
    {
        "content": "* Johnson & Johnson announces agreement to acquire Vogue International",
        "date": "06022016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson to acquire Vogue International for about $3.3 bln "
    },
    {
        "content": "* Janssen-Cilag International NV says European Commission (EC) has approved use of TREVICTA for maintenance treatment of schizophrenia in adult patients  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05312016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-European Commission approves Johnson & Johnson's TREVICTA "
    },
    {
        "content": "NEW YORK California has accused Johnson & Johnson of failing to warn doctors and patients about the severity and frequency of complications associated with its pelvic mesh devices.",
        "date": "05242016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "California sues Johnson & Johnson over marketing for pelvic mesh "
    },
    {
        "content": "NEW YORK  May 24 California has accused Johnson & Johnson of failing to warn doctors and patients about the severity and frequency of complications associated with its pelvic mesh devices.",
        "date": "05242016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-California sues Johnson & Johnson over marketing for pelvic mesh "
    },
    {
        "content": "Johnson & Johnson and its Ethicon unit have reached a settlement in a lawsuit currently on appeal before Texas' highest court over whether a $1.2 million verdict for a woman claiming to have been injured by a defective pelvic mesh device had been wrongly overturned.",
        "date": "05232016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J settles pelvic mesh appeal before Texas Supreme Court "
    },
    {
        "content": "NEW YORK Johnson & Johnson will keep arguing in court that its talc-based powders are safe  an outside lawyer who has defended the company in lawsuits said  even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.",
        "date": "05182016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J to stand behind talc's safety at upcoming trials: lawyer "
    },
    {
        "content": "* Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies",
        "date": "05172016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Johnson & Johnson says collaborating with HP Inc's unit "
    },
    {
        "content": "NEW YORK  May 17 Johnson & Johnson will keep arguing in court that its talc-based powders are safe  an outside lawyer who has defended the company in lawsuits said  even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.",
        "date": "05182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "REFILE-J&J to stand behind talc's safety at upcoming trials -lawyer "
    },
    {
        "content": "May 18 - Johnson & Johnson will keep arguing in court that its talc-based powders are safe  an outside lawyer who has defended the company in lawsuits said  even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.",
        "date": "05182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J to stand behind talc's safety at upcoming trials -lawyer "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  May 11 (Fitch) Fitch Ratings has assigned a 'AAA' rating to Johnson &  Johnson's (JNJ) euro notes offering. The Rating Outlook is Stable. JNJ intends  to use the net proceeds from the issuance for share repurchases  debt reduction  and general corporate purposes. A complete list of JNJ's ratings follows at the  end of this press release. KEY RATING DRIVERS The company's 'AAA' rating reflects the following: --JNJ continues to ge",
        "date": "05112016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Fitch Rates Johnson & Johnson's Euro Notes Offering 'AAA'; Outlook Stable "
    },
    {
        "content": "Spending on advertising targeting women who may have claims involving Johnson & Johnson's talc-powder products and ovarian cancer has skyrocketed in the wake of two multimillion-dollar plaintiffs' verdicts this year  according to data from X Ante  which tracks mass-tort marketing.",
        "date": "05052016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Talc-powder lawsuit advertising jumps after back-to-back verdicts "
    },
    {
        "content": "NEW YORK Johnson & Johnson  was ordered by a U.S. jury on Monday to pay $55 million to a woman who said that using the company\u2019s talc-powder products for feminine hygiene caused her to develop ovarian cancer.",
        "date": "05032016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson ordered to pay $55 mln in talc-powder trial "
    },
    {
        "content": "Jurors in Missouri heard closing arguments Friday following a three-week state court trial over claims that Johnson & Johnson's talc-based powders caused a woman to develop ovarian cancer.",
        "date": "04292016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Jury hears closing arguments in J&J talc powder trial in St. Louis "
    },
    {
        "content": "Five plaintiffs suing Johnson & Johnson and its DePuy unit over Pinnacle hip implants have asked a federal judge in Texas to let them collect the full $360 million in punitive damages they were awarded last month  calling a state cap that could reduce it to less than $10 million unconstitutional.",
        "date": "04222016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J Pinnacle plaintiffs fight for full $360 mln punitive-damage award "
    },
    {
        "content": "Johnson & Johnson  beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar  and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year.",
        "date": "04192016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J shares hit new high on strong drug sales  weaker dollar "
    },
    {
        "content": "April 19 Johnson & Johnson beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar  and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year.",
        "date": "04192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J shares hit new high on strong drug sales  weaker dollar "
    },
    {
        "content": "April 19 Johnson & Johnson reported a 0.6 percent rise in first-quarter sales  constrained by the strong dollar and Venezuela's currency devaluation.",
        "date": "04192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J first-quarter sales rise marginally "
    },
    {
        "content": "NEW YORK  April 14 After lagging a six-year healthcare sector run fueled by fast-growing biotech companies  Johnson & Johnson shares have beaten the group in 2016 as investors turn to safety in rocky equity markets.",
        "date": "04142016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Investors find safety in J&J shares  but run could stall "
    },
    {
        "content": "Johnson & Johnson ignored decades of scientific evidence linking talc-based powder to ovarian cancer  a lawyer for a woman suing the company told jurors in Missouri state court on Tuesday at the start of the latest trial amid roughly 1 200 similar cases.",
        "date": "04132016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Second state-court trial over J&J talc powder kicks off in Missouri "
    },
    {
        "content": "A Johnson & Johnson subsidiary must pay more than $1.3 million for luring away a rival medical device maker's employee in order to win the business of a major client  a U.S. appeals court said on Tuesday.",
        "date": "04132016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson unit liable for poaching rival's employee - 8th Circuit "
    },
    {
        "content": "Rembrandt Vision Technologies will get a new trial of its patent-infringement claims against Johnson & Johnson Vision Care because of misconduct by a defense expert  a divided appellate court held Thursday.",
        "date": "04082016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Federal Circuit reverses J&J's win on contact-lens patent "
    },
    {
        "content": "European regulators on Friday recommended approving with conditions Johnson & Johnson's blood cancer drug  saying they would need to evaluate additional data from two ongoing studies.",
        "date": "04012016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "EU recommends conditional approval of J&J's blood cancer drug "
    },
    {
        "content": "April 1 European regulators on Friday recommended approving with conditions Johnson & Johnson's  blood cancer drug  saying they would need to evaluate additional data from two ongoing studies.",
        "date": "04012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-EU recommends conditional approval of J&J's blood cancer drug "
    },
    {
        "content": "April 1 European regulators recommended approving Johnson & Johnson's blood cancer drug with conditions on Friday  saying they would need to evaluate additional data from two ongoing studies on the antibody treatment.",
        "date": "04012016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "EU recommends conditional approval for J&J's blood cancer drug "
    },
    {
        "content": "LONDON  March 21 A cancer drug originally discovered in Britain has finally been endorsed for treating advanced prostate cancer before chemotherapy on the country's state health service in a change of heart by the cost agency NICE.",
        "date": "03212016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UK cost agency backs J&J cancer drug in change of heart "
    },
    {
        "content": "March 18 Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial  the company said on Friday  bolstering prospects of its approval for the additional use.",
        "date": "03182016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "RPT-UPDATE 1-J&J psoriasis drug Stelara eases Crohn's disease in second trial "
    },
    {
        "content": "Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial  the company said on Friday  bolstering prospects of its approval for the additional use.",
        "date": "03182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J psoriasis drug Stelara eases Crohn's disease in second trial "
    },
    {
        "content": "March 18 Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial  the company said on Friday  bolstering prospects of its approval for the additional use.",
        "date": "03182016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J psoriasis drug Stelara tames Crohn's disease in second trial "
    },
    {
        "content": "March 16 Johnson & Johnson Says Ceo Alex Gorsky's 2015 Total Compensation Was $23.8 Mln Vs $25 Mln In 2014 - Sec filing \u007f",
        "date": "03162016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-J&J CEO Gorsky's 2015 total compensation was $23.8 mln "
    },
    {
        "content": "NEW YORK Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants.",
        "date": "03172016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J hit with $500 mln verdict in hip implant trial "
    },
    {
        "content": "NEW YORK Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants.",
        "date": "03172016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson hit with $500 million verdict in hip implant trial "
    },
    {
        "content": "NEW YORK  March 17 Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants.",
        "date": "03172016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J hit with $500 mln verdict in hip implant trial "
    },
    {
        "content": "A federal judge in Pennsylvania has denied a request from Johnson & Johnson and its McNeil subsidiary to bar a marketing expert from testifying on behalf of the plaintiff in the first federal case slated for trial over claims that the popular over-the-counter painkiller Tylenol causes liver damage.",
        "date": "03042016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J loses bid to shut out marketing expert in Tylenol bellwether "
    },
    {
        "content": "LONDON  March 2 A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's healthcare cost-effectiveness agency NICE  which said it could not be confident the medicine represented an effective use of resources.",
        "date": "03022016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UK cost agency rejects leukaemia drug from J&J and AbbVie "
    },
    {
        "content": "Johnson & Johnson  was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades. |\u00a0Video ",
        "date": "02252016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J must pay $72 million for cancer death linked to talcum powder: lawyers "
    },
    {
        "content": "NEW YORK  Feb 24 Consumers expressed concern on social media about a talc-based baby powder made by Johnson & Johnson on Wednesday after a Missouri jury ordered the company to pay $72 million in damages to the family of a woman who said her death from cancer was linked to use of the product.",
        "date": "02242016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Social media users concerned over J&J talc powder after verdict "
    },
    {
        "content": "NEW YORK  Feb 25 The $72 million verdict this week against Johnson & Johnson in a U.S. case alleging links between talc-based powder and ovarian cancer has prompted global headlines  social media buzz and calls to lawyers from would-be plaintiffs.",
        "date": "02262016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Big verdict doesn't assure more wins for plaintiffs in talc-cancer cases "
    },
    {
        "content": "Johnson & Johnson was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades.",
        "date": "02232016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J must pay $72 mln for cancer death linked to talcum powder - lawyers "
    },
    {
        "content": "Feb 23 Johnson & Johnson was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades.",
        "date": "02232016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-J&J must pay $72 mln for cancer death linked to talcum powder - lawyers "
    },
    {
        "content": "Feb 23 Johnson & Johnson was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades.",
        "date": "02232016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J must pay $72 mln for cancer death linked to talcum powder -lawyers "
    },
    {
        "content": "Feb 3 Pfizer Inc  Johnson and Johnson  and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika  a rapidly spreading mosquito-borne disease linked to birth defects.",
        "date": "02032016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Pfizer  J&J  Merck evaluating technologies for Zika vaccine "
    },
    {
        "content": "Johnson & Johnson's Ethicon Inc unit has reportedly reached a $120 million deal to resolve as many as 3 000 lawsuits alleging that its transvaginal mesh products are defective  marking the first time the manufacturer has agreed to a group settlement in the litigation.",
        "date": "01282016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J reportedly settles first transvaginal mesh suits "
    },
    {
        "content": "Artisan Partners  a major shareholder in Johnson & Johnson  has urged several activists to pressure the consumer products giant to consider major changes that include a potential split  according to sources and documents.             Artisan has asked Johnson & Johnson\u2019s management to consider separating its three divisions \u2013 consumer products  pharmaceuticals and medical devices \u2013 into standalone companies in hopes of unlocking up to $90 billion in enterprise value  said sources fam",
        "date": "01282016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Investor pressures J&J to consider split up: sources "
    },
    {
        "content": "Johnson & Johnson  on Tuesday reported higher-than-expected quarterly earnings  helped by cost cuts and lower taxes  and gave a 2016 profit outlook slightly above Wall Street's.",
        "date": "01262016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J profit beats forecasts  helped by lower taxes  cost cuts "
    },
    {
        "content": "Jan 26 Johnson & Johnson on Tuesday reported higher-than-expected quarterly earnings  helped by cost cuts and lower taxes  and gave a 2016 profit outlook slightly above Wall Street's.",
        "date": "01262016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J profit beats forecasts  helped by lower taxes  cost cuts "
    },
    {
        "content": "* \u007fInnovations joins consortium of three world-leading UK universities and three global pharmaceutical companies to launch 40 million pounds  ($57.22 million) therapeutics fund",
        "date": "01252016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Imperial Innovations joins consortium to launch 40 mln stg therapeutics fund\u007f "
    },
    {
        "content": "Johnson & Johnson  said on Tuesday it would cut about 3 000 jobs within its medical devices unit over the next two years  or about 4 to 6 percent of the struggling division's global workforce  to generate annual cost savings of up to $1 billion and focus on more innovative products.",
        "date": "01192016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J to cut 3 000 jobs in struggling device division "
    },
    {
        "content": "NEW YORK The U.S. Supreme Court said on Tuesday it will not hear Johnson & Johnson\u2019s appeal of a $140 million judgment in a lawsuit alleging it failed to warn that Children\u2019s Motrin pain and fever medication could cause a devastating skin condition.",
        "date": "01192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. top court won't hear J&J appeal of $140 million judgment "
    },
    {
        "content": "NEW YORK  Jan 19 The U.S. Supreme Court said on Tuesday it will not hear Johnson & Johnson's appeal of a $140 million judgment in a lawsuit alleging it failed to warn that Children's Motrin pain and fever medication could cause a devastating skin condition.",
        "date": "01192016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-U.S. top court won't hear J&J appeal of $140 million judgment "
    },
    {
        "content": "A federal judge in Chicago has rejected Johnson & Johnson's bid to dismiss a potential class action over the company's claims that its Bedtime Bath and Bedtime Lotion are \"clinically proven to help babies sleep better \" breaking ranks with her New York counterpart who tossed parts of a similar suit last month.",
        "date": "01142016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Lights out for J&J's challenge to 'Bedtime' suit in Chicago "
    },
    {
        "content": "WASHINGTON The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.",
        "date": "01112016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. justices reject Johnson & Johnson unit's anti-psychotic drug appeal "
    },
    {
        "content": "WASHINGTON  Jan 11 The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.",
        "date": "01112016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-U.S. justices reject Johnson & Johnson unit's anti-psychotic drug appeal "
    },
    {
        "content": "WASHINGTON  Jan 11 The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary's appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks.",
        "date": "01112016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "U.S. top court rejects Johnson & Johnson unit's appeal of $124 mln penalty "
    },
    {
        "content": "Jan 7 Johnson & Johnson on Thursday said it licensed rights from a Chinese drugmaker to drugs that spur the immune system to help fight diseases  which it hopes will become a key part of a cure for chronic hepatitis B.",
        "date": "01072016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J signs deal with Chinese company for hepatitis B drug "
    },
    {
        "content": "Jan 4 The following bids  mergers  acquisitions and disposals were reported by 2115 GMT on Monday:",
        "date": "01042016",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Jan 5 Eli Lilly and Co's new Jardiance diabetes treatment has begun stealing market share from rival drugs in its class  the company said on Tuesday  bolstered by clinical trial data showing it slashed deaths by 32 percent in patients with Type 2 diabetes.",
        "date": "01052016",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Eli Lilly's diabetes pill takes market share from J&J  Astra "
    },
    {
        "content": "Kentucky reached two separate settlements totaling $39.5 million with Purdue Pharma and Johnson & Johnson  Attorney General Jack Conway said on Wednesday.",
        "date": "12232015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Kentucky reaches $39.5 million settlement with Purdue  Johnson & Johnson "
    },
    {
        "content": "Dec 23 Kentucky reached two separate settlements totaling $39.5 million with Purdue Pharma and Johnson & Johnson   Attorney General Jack Conway said on Wednesday.",
        "date": "12232015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Kentucky reaches $39.5 mln settlement with Purdue  Johnson & Johnson "
    },
    {
        "content": "Johnson & Johnson and Alphabet Inc's life sciences unit have formed an independent company to create far smaller  smarter and less costly robotic-assisted systems for surgery than those sold now by other companies  J&J said on Thursday.",
        "date": "12102015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J  Alphabet aim for smarter  smaller  cheaper surgical robot "
    },
    {
        "content": "Johnson & Johnson's and AbbVie's cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study  paving the way for an expanded approval of the medicine.",
        "date": "12062015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "AbbVie  J&J leukemia drug cuts death risk vs chemo in new patients: study "
    },
    {
        "content": "Dec 6 Johnson & Johnson's and AbbVie's  cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study  paving the way for an expanded approval of the medicine.",
        "date": "12062015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "REFILE-AbbVie  J&J leukemia drug cuts death risk vs chemo in new patients-study "
    },
    {
        "content": "In its bid to overturn a $140 million award over Children's Motrin  Johnson & Johnson is asking the U.S. Supreme Court to clarify what constitutes \"clear evidence\" that federal regulators would reject proposed changes to a drug's warning label.",
        "date": "11132015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Case to Watch: J&J asks SCOTUS to clarify preemption standard "
    },
    {
        "content": "Nov 16 U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer.",
        "date": "11162015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FDA approves J&J drug for advanced multiple myeloma "
    },
    {
        "content": "A long-acting two-drug injection given once every eight weeks worked as well as three daily pills in suppressing HIV  the virus that causes AIDS  according to a clinical trial backed by Johnson & Johnson and GlaxoSmithKline.",
        "date": "11032015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Bi-monthly injection blocks HIV in study from J&J and GSK "
    },
    {
        "content": "Nov 3 A cocktail of Johnson & Johnson's  HIV compound and an experimental drug from ViiV Healthcare met the main goal of a mid-stage study  becoming the second combination to do so.",
        "date": "11032015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson HIV combination succeeds in mid-stage study "
    },
    {
        "content": "The U.S. Food and Drug Administration said it approved Johnson & Johnson's chemotherapy to treat specific soft-tissue sarcomas (STS) that have spread to other parts of the body or cannot be removed by surgery.",
        "date": "10232015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FDA clears J&J's chemotherapy for certain soft tissue sarcomas "
    },
    {
        "content": "* Course of therapy to cost about $40 500 in U.S.   (Adds detail  company comment)",
        "date": "10232015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-FDA clears J&J's chemotherapy for certain soft tissue sarcomas "
    },
    {
        "content": "Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease  according to data from a late stage trial  providing ammunition for a potential expanded approval of the medicine.",
        "date": "10192015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson's Stelara succeeds in Phase III Crohn's disease trial "
    },
    {
        "content": "Oct 19 Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease  according to data from a late stage trial  providing ammunition for a potential expanded approval of the medicine.",
        "date": "10192015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's Stelara succeeds in Phase III Crohn's disease trial "
    },
    {
        "content": "Oct 16 - Johnson & Johnson has lost its bid to keep three lawsuits that bring together claims from more than 200 plaintiffs alleging a link between talcum-powder products and ovarian cancer from returning to state court in St. Louis.",
        "date": "10162015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "More than 200 J&J talcum-powder cancer plaintiffs return to state court "
    },
    {
        "content": "Johnson & Johnson  reported third-quarter sales well below Wall Street estimates  hurt by the stronger dollar and disappointing demand for its Remicade arthritis drug and its Xarelto blood clot preventer. |\u00a0Video ",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J third-quarter sales miss mark  hurt by strong dollar "
    },
    {
        "content": "Johnson & Johnson  said the proven ability of Eli Lilly and Co's  rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the entire class of drugs  including J&J's own approved Invokana treatment.",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J says its diabetes drug should have same survival edge as Lilly's "
    },
    {
        "content": "Johnson & Johnson has begun a clinical trial of a two-shot Ebola vaccine in Sierra Leone  underlining its determination to push ahead with development  even as the epidemic fades out in West Africa.",
        "date": "10092015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J starts vaccine trial in Sierra Leone  even as Ebola fades "
    },
    {
        "content": "Oct 13 Johnson & Johnson said on Tuesday that the ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is likely to benefit the entire class of drugs  including J&J's own approved Invokana treatment.",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J says Jardiance survival benefit likely to be seen by Invokana "
    },
    {
        "content": "Oct 9 Johnson & Johnson said it has begun a safety and immunogenicity clinical trial of a preventive Ebola vaccine regimen in Sierra Leone.",
        "date": "10092015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J starts clinical trial of Ebola vaccine in Sierra Leone "
    },
    {
        "content": "* Share buyback of up to $10 bln   (Adds analyst comment  product sales data   updates stock price)",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J 3rd-quarter sales miss mark  hurt by strong dollar "
    },
    {
        "content": "Oct 13 Johnson & Johnson reported a 7.4 percent fall in quarterly sales as the impact of a strong dollar more than offset higher sales of its mainstay older drugs.",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Strong dollar eats into J&J quarterly sales "
    },
    {
        "content": "Drugmaker Johnson & Johnson  said it plans to buy back up to $10 billion of common stock over time.",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson plans to buy back shares up to $10 billion "
    },
    {
        "content": "Oct 13 Drugmaker Johnson & Johnson said it would buy back up to $10 billion of common stock over time.",
        "date": "10132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson to buy back shares up to $10 bln "
    },
    {
        "content": "Johnson & Johnson  on Tuesday said it was selling its widely used Splenda sugar substitute to privately held Heartland Food Products Group in order to focus on other consumer brands.",
        "date": "08252015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J sells popular Splenda sugar substitute to Heartland Food "
    },
    {
        "content": "Aug 25 Johnson & Johnson on Tuesday said it was selling its widely used Splenda sugar substitute to privately held Heartland Food Products Group in order to focus on other consumer brands.",
        "date": "08252015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J sells popular Splenda sugar substitute to Heartland Food "
    },
    {
        "content": "Nearly two years after Johnson & Johnson and its Janssen Pharmaceutical unit reached a $2.2 billion settlement with the U.S. Justice Department over the marketing of the antipsychotic drug Risperdal  the drug companies are facing a similar suit by the Cherokee Nation.",
        "date": "07282015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Cherokee Nation sues J&J for Risperdal refund "
    },
    {
        "content": "Advertising company Interpublic Group of Cos Inc's  revenue trumped expectations for the seventh straight quarter as higher advertising spending by U.S. businesses made up for the strong dollar's impact on international revenue.",
        "date": "07222015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Interpublic reports better-than-expected revenue "
    },
    {
        "content": "Johnson & Johnson on Tuesday reported sharply lower sales in the second quarter  and cited a stronger U.S. dollar  disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition.",
        "date": "07142015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson second-quarter sales wilt on strong dollar  weak device sales "
    },
    {
        "content": "July 14 Johnson & Johnson on Tuesday reported sharply lower sales in the second quarter  and cited a stronger U.S. dollar  disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition.",
        "date": "07142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J 2nd-qtr sales wilt on strong dollar  weak device sales "
    },
    {
        "content": "* J&J CFO says does not expect Greece debt resolution to affect company sales  earnings unless there is significant change from expected resolution",
        "date": "07142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J CFO sees little impact from Greece debt resolution "
    },
    {
        "content": "July 14 Johnson & Johnson reported a 4 percent rise in quarterly profit as sales of its mainstay older drugs managed to offset the impact of a strong dollar on overseas revenue.",
        "date": "07142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J profit rises 4 pct on pharma sales "
    },
    {
        "content": "Lawyers for six women suing Johnson & Johnson over injuries allegedly caused by its power morcellator medical devices have sought to consolidate more than 20 similar lawsuits in Kansas federal court.",
        "date": "06222015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "MDL sought for Johnson & Johnson power morcellator lawsuits "
    },
    {
        "content": "WASHINGTON  June 15 U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak  a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.",
        "date": "06152015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "WRAPUP 2-U.S. industrial output hurt by weakness in manufacturing  mining "
    },
    {
        "content": "COPENHAGEN  June 8 Shares in Genmab  rose almost 3 percent on Monday after partner Johnson and Johnson's announcement late on Friday that the companies have applied to U.S. authorities for a licence to market their blood cancer drug daratumumab.",
        "date": "06082015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Genmab shares rise on cancer drug's FDA licence application "
    },
    {
        "content": "WASHINGTON  May 29 The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls  a resurgent dollar and disruptions at West Coast ports  but activity already has rebounded modestly.",
        "date": "05292015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "WRAPUP 4-U.S. economy contracts in Q1; dollar hurts corporate profits "
    },
    {
        "content": "The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year  the Wall Street Journal reported.",
        "date": "05272015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FBI probing what J&J knew about uterine surgery device: WSJ "
    },
    {
        "content": "May 27 The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year  the Wall Street Journal reported.",
        "date": "05272015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-FBI probing what J&J knew about uterine surgery device - WSJ "
    },
    {
        "content": "U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019  and is testing dozens of new uses for existing medicines.",
        "date": "05202015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J to submit at least 10 new drugs for approval by 2019 "
    },
    {
        "content": "May 20 U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019  and is testing dozens of new uses for existing medicines.",
        "date": "05202015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019 "
    },
    {
        "content": "May 19 Achillion Pharmaceuticals Inc  said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.",
        "date": "05202015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19) "
    },
    {
        "content": "Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.",
        "date": "05192015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Achillion partners with J&J to develop hepatitis C drugs "
    },
    {
        "content": "The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca  Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.",
        "date": "05152015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA warns on newer class of type 2 diabetes drugs "
    },
    {
        "content": "May 19 Achillion Pharmaceuticals Inc  said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.",
        "date": "05192015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Achillion partners with J&J to develop hep C drugs "
    },
    {
        "content": "May 19 Achillion Pharmaceuticals Inc  said it will collaborate with Johnson & Johnson to develop and market one or more of its hepatitis C drugs.",
        "date": "05192015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Achillion partners with J&J to develop hep C drugs "
    },
    {
        "content": "May 15 The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca  Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.",
        "date": "05152015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-U.S. FDA warns on newer class of type 2 diabetes drugs "
    },
    {
        "content": "May 19 The U.S. Food and Drug Administration approved a longer-acting version of Johnson & Johnson's  schizophrenia treatment  developed by the company's Janssen Pharmaceuticals unit.",
        "date": "05192015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "FDA approves longer-acting version of J&J's schizophrenia drug "
    },
    {
        "content": "NEW YORK Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on \"compassionate use\" requests  in which desperate patients ask drugmakers to let them take an experimental medication  the company announced on Thursday.",
        "date": "05072015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J to consult ethicists on requests for experimental drugs "
    },
    {
        "content": "NEW YORK  May 7 Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on \"compassionate use\" requests  in which desperate patients ask drugmakers to let them take an experimental medication  the company announced on Thursday.",
        "date": "05072015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-J&J to consult ethicists on requests for experimental drugs "
    },
    {
        "content": "Advertising agency Interpublic Group of Cos Inc's  quarterly revenue trumped expectations as higher ad spending by U.S. businesses made up for the strong dollar's impact on international revenue.",
        "date": "04242015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Interpublic revenue beats estimates on higher U.S. ad spending "
    },
    {
        "content": "* Says achieves 10 million dollar milestone in daratumumab collaboration with Janssen  a pharmaceutical company of Johnson & Johnson",
        "date": "04162015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "BRIEF-Genmab reach $10 mln milestone in Johnson & Johnson collaboration "
    },
    {
        "content": "WASHINGTON  April 15 U.S. industrial output posted its biggest drop in more than 2-1/2 years in March in part as oil and gas well drilling plummeted  highlighting the negative impact of lower crude prices and a strong dollar on the economy.",
        "date": "04152015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "WRAPUP 3-Mining  utilities sink U.S. industrial production "
    },
    {
        "content": "SEATTLE  April 13 International Business Machines Corp  deepening its partnership with Apple Inc  to make use of health information gathered by millions of Apple devices  is creating  a unit dedicated to providing data analytics to the healthcare sector.",
        "date": "04132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "IBM launches new health unit  teams up with Apple  J&J  Medtronic "
    },
    {
        "content": "NEW YORK The Dow and S&P 500 ended higher on Tuesday  helped by energy stocks and quarterly earnings reports that topped modest expectations following worries about a strong dollar.",
        "date": "04142015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Wall Street ends higher after bounce in oil prices "
    },
    {
        "content": "Healthcare conglomerate Johnson & Johnson cut its full-year profit forecast on Tuesday  saying it expected a strong dollar to keep hurting its international business.",
        "date": "04142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J cuts full-year forecast due to strong dollar "
    },
    {
        "content": "* J&J expects to fend off Remicade biosimilar for nearly 3 years",
        "date": "04142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J cuts full-year forecast due to strong dollar "
    },
    {
        "content": "NEW YORK  April 14 U.S. stocks rose modestly on Tuesday as investors digested the initial major earnings of the first-quarter reporting season  which showed some weakness despite companies topping lowered expectations.",
        "date": "04142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "REFILE-US STOCKS-Wall St edges up after JPMorgan  J&J results "
    },
    {
        "content": "* Futures: Dow down 3 pts  S&P down 2 pts  Nasdaq up 1.5 pt   (Updates with Wells results  retail sales data)",
        "date": "04142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "US STOCKS-Futures point to flat open after JPMorgan  J&J results "
    },
    {
        "content": "April 14 Johnson & Johnson reported an 8.6 percent fall in quarterly profit as the impact of a strong dollar on overseas revenue offset growing sales of its mainstay older drugs.",
        "date": "04142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's first-qtr profit falls 8.6 pct "
    },
    {
        "content": "NEW YORK  March 30 GlaxoSmithKline Plc  has agreed to settle a lawsuit by Johnson & Johnson  accusing it of using false advertising at the start of the U.S. allergy season to grab market share.",
        "date": "03302015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J  Glaxo settle U.S. lawsuit over allergy ads "
    },
    {
        "content": "An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc and Johnson & Johnson's Imbruvica  after the treatment was successful against two similar forms of cancer in combination with other drugs.",
        "date": "03162015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Pharmacyclics cancer drug successful as combination therapy: independent panel "
    },
    {
        "content": "NEW YORK  March 12 Johnson & Johnson  sued rival drugmaker GlaxoSmithKline PLC on Thursday  alleging that Glaxo is trying to unlawfully grab market share with false advertising at the start of spring allergy season in the United States.",
        "date": "03122015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson sues Glaxo over allergy ads as spring nears "
    },
    {
        "content": "March 16 An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc  and Johnson & Johnson's Imbruvica  after the treatment was successful against two similar forms of cancer in combination with other drugs.",
        "date": "03162015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Pharmacyclics cancer drug successful as combination therapy - independent panel "
    },
    {
        "content": "March 16 An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc  and Johnson & Johnson's Imbruvica  after the treatment was successful in treating two types of cancer in combination with other drugs.",
        "date": "03162015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-Independent panel recommends unblinding study after Imbruvica shows clear benefit "
    },
    {
        "content": "Four days into a bellwether trial in West Virginia federal court  Johnson & Johnson's Ethicon Inc has reached a settlement in a lawsuit from a woman who said she was injured by one of its transvaginal mesh devices.",
        "date": "03092015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Ethicon settles bellwether mesh case mid-trial in West Virginia "
    },
    {
        "content": "WASHINGTON  March 10 A Johnson & Johnson  subsidiary pleaded guilty on Tuesday to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve the case  the U.S. Department of Justice said on Tuesday.",
        "date": "03102015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Tylenol maker to pay $25 mln for selling metal-contaminated drugs "
    },
    {
        "content": "WASHINGTON A Johnson & Johnson subsidiary pleaded guilty on Tuesday to selling liquid medicine contaminated with metal and agreed to pay $25 million to resolve the case  the U.S. Department of Justice said on Tuesday.",
        "date": "03102015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Tylenol maker to pay $25 million for selling metal-contaminated drugs "
    },
    {
        "content": "Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days  the Financial Times reported  citing sources.",
        "date": "03042015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J nearing deal to buy cancer drug maker Pharmacyclics: FT "
    },
    {
        "content": "A California jury on Thursday ordered Johnson & Johnson's Ethicon Inc unit to pay $5.7 million in the first trial over injuries blamed on the TVT Abbrevo  one of numerous transvaginal mesh products that are the subject of thousands of lawsuits.",
        "date": "03052015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Johnson & Johnson ordered to pay $5.7 million in California mesh trial "
    },
    {
        "content": "March 4 Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days  the Financial Times reported  citing sources.",
        "date": "03042015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J nearing deal to buy cancer drug maker Pharmacyclics - FT "
    },
    {
        "content": "A California jury on Thursday ordered Johnson & Johnson's Ethicon Inc unit to pay $5.7 million in the first trial over injuries blamed on the TVT Abbrevo  one of numerous transvaginal mesh products that are the subject of thousands of lawsuits.",
        "date": "03052015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson ordered to pay $5.7 mln in California mesh trial "
    },
    {
        "content": "* Johnson & Johnson nearing deal to buy Pharmacyclics Inc - Financial Times  Source text (http://on.ft.com/1EhbLrQ)",
        "date": "03042015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "BRIEF-J&J nearing deal to buy Pharmacyclics - FT "
    },
    {
        "content": "March 5 A California jury on Thursday ordered Johnson & Johnson's Ethicon Inc unit to pay $5.7 million in the first trial over injuries blamed on the TVT Abbrevo  one of numerous transvaginal mesh products that are the subject of thousands of lawsuits.",
        "date": "03052015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Johnson & Johnson ordered to pay $5.7 mln in California mesh trial "
    },
    {
        "content": "March 5 A California jury on Thursday ordered Johnson & Johnson's Ethicon Inc to pay $5.6 million in the first trial over injuries blamed on the TVT Abbrevo  one of numerous transvaginal mesh products that are the subject of thousands of lawsuits.",
        "date": "03052015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "CORRECTED-Johnson & Johnson ordered to pay $5.6 mln in California mesh trial "
    },
    {
        "content": "March 2 The following bids  mergers  acquisitions and disposals were reported by 2100 GMT on Monday:",
        "date": "03022015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "NEW YORK U.S. pharmaceutical and medical equipment maker Johnson & Johnson  said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health  for $1.9 billion  completing its exit from the cardiovascular stent business.",
        "date": "03022015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion "
    },
    {
        "content": "NEW YORK  March 2 U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9 billion  completing its exit from the cardiovascular stent business.",
        "date": "03022015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln "
    },
    {
        "content": "NEW YORK  March 2 Cardinal Health said on Monday that it would buy Johnson & Johnson's Cordis vascular technology unit for $1.9 billion and that the acquisition would boost 2017 earnings by 20 cents per share.",
        "date": "03022015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln "
    },
    {
        "content": "Johnson & Johnson's Janssen Pharmaceuticals was hit with a $2.5 million verdict for failing to warn that its antipsychotic drug Risperdal could cause male breast growth.",
        "date": "02242015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J's Janssen hit with $2.5 mln verdict in Risperdal suit "
    },
    {
        "content": "Feb 26 South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million  upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.",
        "date": "02262015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "South Carolina court orders J&J to pay $136 mln in Risperdal case "
    },
    {
        "content": "South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million  upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.",
        "date": "02262015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "South Carolina court orders Johnson & Johnson to pay $136 million in Risperdal case "
    },
    {
        "content": "Cancer drug maker Pharmacyclics Inc  is exploring a sale and has attracted interest from Johnson & Johnson  and Novartis AG   Bloomberg reported.",
        "date": "02252015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Pharmacyclics mulls sale; J&J  Novartis interested: Bloomberg "
    },
    {
        "content": "Feb 25 Cancer drug maker Pharmacyclics Inc  is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG  Bloomberg reported.",
        "date": "02252015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-Pharmacyclics mulls sale; J&J  Novartis interested - Bloomberg "
    },
    {
        "content": "Feb 25 Cancer drugmaker Pharmacyclics Inc  is exploring a possible sale of the company and has attracted interest from Johnson & Johnson and Novartis AG  Bloomberg reported  citing people familiar the matter.",
        "date": "02252015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Pharmacyclics mulls selling itself; J&J  Novartis interested-Bloomberg "
    },
    {
        "content": "Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson & Johnson to settle a long-running lawsuit over Boston Scientific's 2005 acquisition of rival Guidant.",
        "date": "02172015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Boston Scientific to pay J&J $600 million to settle Guidant suit "
    },
    {
        "content": "Feb 17 Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson & Johnson to settle a long-running lawsuit over Boston Scientific's 2005 acquisition of rival Guidant.",
        "date": "02172015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Boston Scientific to pay J&J $600 mln to settle Guidant suit "
    },
    {
        "content": "(The following statement was released by the rating agency) CHICAGO  February 17 (Fitch) Boston Scientific Corp.'s (NYSE: BSX) ratings are  unaffected by its recent settlement with Johnson & Johnson (NYSE: JNJ) regarding  litigation associated with BSX's acquisition of Guidant in 2006  according to  Fitch Ratings.  The settlement calls for BSX to pay $600 million to JNJ during 2015. BSX will  make two $300 million dollar payments  primarily using balance sheet cash  without taking on any additio",
        "date": "02172015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Fitch: Boston Scientific's Settlement Reduces Liability Risk but Also Liquidity "
    },
    {
        "content": "Feb 17 Medical device maker Boston Scientific Corp on Tuesday said it has agreed to pay $600 million to Johnson & Johnson to settle a long-running breach of merger lawsuit over Boston Scientific's 2005 acquisition of rival Guidant.",
        "date": "02172015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Boston Scientific to pay J&J $600 mln to settle Guidant suit "
    },
    {
        "content": "Feb 17 Pharmacyclics Inc said its cancer drug developed with a Johnson & Johnson unit improved overall response rate in high-risk leukemia patients.",
        "date": "02172015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J-Pharmacyclics drug shows potential in high-risk leukemia patients "
    },
    {
        "content": "NEW YORK  Feb 11 Johnson & Johnson has dropped its request to investigate the source of what it said were illegal phone calls that may have resulted in baseless lawsuits over transvaginal mesh devices against its Ethicon Inc subsidiary.",
        "date": "02112015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J drops bid to probe plaintiff solicitation in mesh cases "
    },
    {
        "content": "NEW YORK  Feb 11 Johnson & Johnson  dropped its request to investigate the source of what it said were illegal phone calls that may have resulted in baseless lawsuits over transvaginal mesh devices against its Ethicon Inc subsidiary.",
        "date": "02112015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-J&J drops bid to probe plaintiff solicitation in mesh cases "
    },
    {
        "content": "The U.S. Food and Drug Administration approved the expanded use of Imbruvica  sold by Johnson & Johnson and Pharmacyclics Inc  to treat Waldenstr\u00f6m's macroglobulinemia (WM)  a rare form of blood cancer for which no specific pharmaceutical therapy exists.",
        "date": "01292015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "FDA expands use of Imbruvica to treat rare form of blood cancer "
    },
    {
        "content": "Jan 29 The U.S. Food and Drug Administration approved the expanded use of Imbruvica  sold by Johnson & Johnson and Pharmacyclics Inc  to treat Waldenstr\u00f6m's macroglobulinemia (WM)  a rare form of blood cancer for which no specific pharmaceutical therapy exists.",
        "date": "01292015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-FDA expands use of Imbruvica to treat rare form of blood cancer "
    },
    {
        "content": "NEW YORK Lawyers for thousands of women suing Johnson & Johnson\u2019s Ethicon Inc over transvaginal mesh devices are fighting back against the company\u2019s claim that illegal phone solicitations may have resulted in baseless lawsuits.",
        "date": "01232015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Plaintiffs\u2019 lawyers reject J&J claims of fraud in mesh lawsuits "
    },
    {
        "content": "NEW YORK  Jan 23 Lawyers for thousands of women suing Johnson & Johnson's Ethicon Inc over transvaginal mesh devices are fighting back against the company's claim that illegal phone solicitations may have resulted in baseless lawsuits.",
        "date": "01232015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Plaintiffs' lawyers reject J&J claims of fraud in mesh lawsuits "
    },
    {
        "content": "LONDON FIFA have rejected suggestions that major sponsors were cutting their ties with the organization because it was a \"toxic brand\"  saying on Friday that they were in advanced negotiations with new sponsors eager to replace the old.",
        "date": "01232015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "New sponsors ready to replace old say beleaguered FIFA "
    },
    {
        "content": "NEW YORK  Jan 21 For more than eight years  Johnson & Johnson has pursued billions of dollars in damages against Boston Scientific Corp after the latter won a controversial - and ultimately ill-fated - bidding war for device maker Guidant.",
        "date": "01222015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's $7.2 bln claim against Boston Scientific now with U.S. judge "
    },
    {
        "content": "Johnson & Johnson reported lower-than-expected quarterly sales as a stronger dollar offset higher sales of the Band-Aid maker's new drugs and older treatments.",
        "date": "01202015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Stronger dollar hurts J&J's quarterly sales "
    },
    {
        "content": "NEW YORK For more than eight years  Johnson & Johnson  has pursued billions of dollars in damages against Boston Scientific Corp  after the latter won a controversial \u2013 and ultimately ill-fated \u2013 bidding war for device maker Guidant.",
        "date": "01222015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson's $7.2 billion claim against Boston Scientific now with U.S. judge "
    },
    {
        "content": "Jan 20 Johnson & Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year  and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck & Co.",
        "date": "01202015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Johnson & Johnson's forex warning a sign for rival drugmakers "
    },
    {
        "content": "Jan 20 Johnson & Johnson reported lower-than-expected quarterly sales as a stronger dollar offset higher sales of the Band-Aid maker's new drugs and older treatments.",
        "date": "01202015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 1-Stronger dollar hurts J&J's quarterly sales "
    },
    {
        "content": "Jan 20 Johnson & Johnson reported a slightly better-than-expected quarterly profit as surging sales of new drugs and mainstay older brands offset weak demand for medical devices and consumer healthcare products.",
        "date": "01202015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J's profit beats estimates on sales of new drugs "
    },
    {
        "content": "Depomed Inc  on Thursday said it has agreed to pay $1.05 billion to acquire the U.S. rights to Johnson & Johnson's   Nucynta opioid pain drug franchise  giving the smaller company a new flagship product expected to significantly add to  revenue and earnings.",
        "date": "01152015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Depomed to pay $1 billion for J&J pain drug franchise "
    },
    {
        "content": "LONDON Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.",
        "date": "01162015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J Ebola vaccine gets 100 million euros to speed development "
    },
    {
        "content": "Jan 15 Depomed Inc on Thursday said it has agreed to pay $1.05 billion to acquire the U.S. rights to Johnson & Johnson's  Nucynta opioid pain drug franchise  giving the smaller company a new flagship product expected to significantly add to  revenue and earnings.",
        "date": "01152015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "Depomed to pay $1 bln for J&J pain drug franchise "
    },
    {
        "content": "LONDON  Jan 16 Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe's Innovative Medicines Initiative to speed development.",
        "date": "01162015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J Ebola vaccine gets 100 mln euros to speed development "
    },
    {
        "content": "NEW YORK Johnson & Johnson said in a court filing on Wednesday that women are being illegally solicited by unknown callers trying to persuade them to sue over transvaginal mesh devices  which are the subject of more than 35 000 lawsuits against its Ethicon Inc subsidiary.",
        "date": "01142015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J says women being illegally solicited to join in mesh lawsuits "
    },
    {
        "content": "Jan 13 Johnson & Johnson on Tuesday announced a licensing deal with Vedanta Biosciences to develop the privately held company's lead microbiome-based drug candidate for inflammatory bowel disorders  such as Crohn's disease and ulcerative colitis.",
        "date": "01132015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J in deal to develop microbiome drug for bowel diseases "
    },
    {
        "content": "Jan 12 The following bids  mergers  acquisitions and disposals were reported by 2100 GMT on Monday:",
        "date": "01122015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "LONDON/ZURICH Johnson & Johnson boosted its research efforts into battling Alzheimer's on Monday  striking a deal potentially worth more than $500 million to develop anti-tau vaccines with Swiss biotech firm AC Immune.",
        "date": "01122015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J strikes Alzheimer's research deal with Swiss firm AC Immune "
    },
    {
        "content": "* CEO says listing is among options for company's future   (Adds comments from AC Immune CEO)",
        "date": "01122015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 2-J&J strikes Alzheimer's research deal with Swiss firm AC Immune "
    },
    {
        "content": "Jan 12 Swiss biotech firm AC Immune said on Monday it had struck an exclusive worldwide license agreement potentially worth up to $509 million with Johnson & Johnson  to develop so-called anti-Tau vaccines for Alzheimer's disease.",
        "date": "01122015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "AC Immune strikes up to $509 mln Alzheimer's deal with J&J "
    },
    {
        "content": "Jan 9 Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of Johnson & Johnson's blood thinner  Xarelto  in a late-stage study.",
        "date": "01092015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "Portola's drug reverses effect of J&J's blood thinner Xarelto "
    },
    {
        "content": "LONDON Johnson & Johnson has started clinical trials of its experimental Ebola vaccine  which uses a booster from Denmark's Bavarian Nordic  making it the third such shot to enter human testing.",
        "date": "01062015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J  Bavarian Nordic start clinical tests in Ebola vaccine race "
    },
    {
        "content": "Johnson & Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel.",
        "date": "01052015",
        "name": "Johnson & Johnson",
        "news_type": "topStory",
        "symbol": "JNJ",
        "title": "J&J buys bowel drug license option from Isis Pharma for $835 million "
    },
    {
        "content": "* First tests in Britain  more planned in U.S. and Africa",
        "date": "01062015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "UPDATE 3-J&J  Bavarian Nordic start clinical tests in Ebola vaccine race "
    },
    {
        "content": "Jan 5 Johnson & Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel.",
        "date": "01052015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J buys bowel drug license option from Isis Pharma for $835 mln "
    },
    {
        "content": "LONDON  Jan 6 U.S. drugmaker Johnson & Johnson  said on Tuesday it had started clinical trials of its experimental Ebola vaccine  which uses a booster developed by Denmark's Bavarian Nordic.",
        "date": "01062015",
        "name": "Johnson & Johnson",
        "news_type": "normal",
        "symbol": "JNJ",
        "title": "J&J and Bavarian Nordic start clinical tests of Ebola vaccine "
    }
]